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1 Introduction 
 
The production of new blood cells is ensured by pluripotent hematopoietic 
stem cells, which reside in specialized niches in the bone marrow (Wilson and 
Trumpp 2006). Haematopoietic stem cells have the ability to self-renew via 
asymmetrical cell division, in which a new stem cell and a hematopoietic 
progenitor cell are generated. This self-renewal ensures the number of stem 
cell (He, Nakada et al. 2009). While all haematopoietic stem cells divide via 
asymmetrical cell division, the frequency of these cell divisions varies. In this 
respect, the most primitive hematopoietic stem cells divide only rarely, 
whereas other stem cells divide more frequently (Zhang and Wang 2008). The 
formation of mature and functional blood cells by the stem cell occurs via 
several consecutive cell divisions and maturation stages (Figure 1). The 
initial asymmetrical cell division is followed by several symmetrical cell 
divisions, during which two identical daughter cells are generated. These 
newly formed cells are more differentiated than their parental cells and 
become increasingly committed to either the myeloid or the lymphoid 
lineage. In the myeloid lineage of haematopoiesis erythrocytes, platelets and 
some white blood cell types, such as monocytes and granulocytes are formed. 
In the lymphoid lineage, T cells, B cells and natural killer cells are generated. 
It may be obvious that this intricate process of haematopoiesis is highly 
regulated by complex signals from the microenvironment to ensure the proper 
generation of sufficient blood cells. Aberrations in cell division and 
differentiation can severely disturb normal haematopoiesis and even result in 
the onset of leukaemia. 
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Figure 1: Overview of haematopoiesis. LTHSC, Long-term repopulating hematopoietic stem 
cell; STHSC, short-term repopulating hematopoietic stem cell; MPP, multipotent progenitor 
cell; CMP, common myeloid progenitor cell; MEP, megakaryocyte-erythroid progenitor cell; 
GMP, granulocyte monocyte progenitor cell; CLP, common lymphoid progenitor cell; RBC, 
red blood cell. Adapted from (Chute, Ross et al. 2010) 
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1.1 Leukaemia 
 
In case of leukaemia, aberrations are often the result of inherited or acquired 
genetic alterations (Rowley 1998). Acute leukaemias are rare diseases, but 
have a disproportionally large effect on cancer survival statistics (Deschler 
and Lubbert 2006). The incidence is approximately 10 cases/100000/years.  
Even if leukaemias represent about 2% of all cancers, they constitute the 
leading cause of death due to cancer in children and persons aged less than 
39 years (Greenlee, Hill-Harmon et al. 2001). The underlying mechanisms 
and factors leading to developing leukaemia in most patients are unknown. 
Several factors are associated with increased risk of developing the disease. 
The risk of developing haematological disorders such as leukaemia increases 
steadily with age (Hiddemann, Kern et al. 1999).  
 
1.1.1 Definition of leukaemia 
Leukaemia is a neoplastic disorder originated from a single haematopoietic 
cell. This change in its genetic making gives the capacity to proliferate 
independently of growth signals and to escape apoptosis. It leads to 
uncontrolled proliferation of hematopoietic cells in the bone marrow blood 
and other tissues.  
A number of different leukaemias are classified according to the course of 
the disease and the predominant type of white blood cell involved (Walter, 
Othus et al. 2013).  
 
1.1.2 Classification of leukaemia 
The degree of maturity and aggressiveness of the leukemic cell population 
allows to qualify chronic and acute leukaemias. Leukaemias are also defined 
as either myelogenous or lymphocytic based on the cell type origin. These 
characteristics are used to designate almost all cases as one of four types—
acute myelogenous, acute lymphocytic, chronic myelogenous, and chronic 
lymphocytic leukaemias. 
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Chronic leukaemias also occur more frequently in adults. These are 
characterized by a more gradual onset and a more protracted course. 
Chronic myelogenous leukaemia, which has a peak incidence among adults 
in their 40s, may remain quiescent for long periods before symptoms such as 
weight loss, low fever, and weakness develop. Before bone marrow 
transplantation and more recently the “Imib” drugs, the median survival was 
about 3 years. Chronic lymphocytic leukaemia occurs primarily in elderly 
people and may be inactive for months or years. The leukaemia itself is rarely 
the cause of death, but it renders the patient vulnerable to infection 
or haemorrhage. 
The acute leukaemias (AL) affect immature cells by a blockage of 
differentiation during the haematopoiesis and a large increase in the numbers 
of immature blood cells primarily in the bone marrow. These leukaemic blasts 
can enter the circulation and spread throughout the body (Porcu, Cripe et al. 
2000). The subsequent accumulation of cells at various stages of incomplete 
maturation reduces the production of healthy haemopoietic elements which 
cause cytopenias. The disease develops rapidly, with symptoms 
including anaemia, sever infections, haemostatic disorders (Colombo, 
Gallipoli et al. 2014), and sometimes swelling of the lymph nodes. Because 
acute leukaemia leads to haemostatic disorders such as haemorrhage, 
thrombosis or disseminated intravascular coagulation (DIC), we focused our 
research on acute myeloid leukaemia (AML) and acute lymphoblastic 
leukaemia (ALL).  
 
1.1.3 Acute myeloid Leukaemia 
Acute myeloid leukaemias are characterized by an increase in the number of 
immature myeloid cells in the marrow. This results in anaemia (fatigue and 
dyspnea), neutropenia (infections) and thrombocytopenia (haemorrhage) 
(Ferrara and Schiffer 2013). Acute myeloid leukaemias are divided in eight 
subtypes M0 through M7, all are recognized following the French-American-
British (FAB) classification (Walter, Othus et al. 2013).  These subtypes are 
characterized by degrees of granulocytic differentiation (M1 – M3) and by 
the degrees of monocytic maturation (M4 and M5). The subtype M6 and M7 
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are characterized by the presence of erythroblasts and megakaryoblasts, 
respectively. The subtype M0 affects the myeloid precursor with minimal 
differentiation (Figure 2) (Venditti, Del Poeta et al. 1997).  
AML can occur in people of all ages. It is the most common leukaemia in 
adults, and has the lowest survival rate among acute leukaemias. The 
prognosis is very poor for older patients. (Redaelli, Lee et al. 2003) (Greenlee, 
Hill-Harmon et al. 2001). AML is primarily a disease of later adulthood. 
42.8% of leukaemia patient are at age >65 years. Age is one of the strongest 
independent predictors of prognosis in AML. The overall survival at 48 
months of intensively treated patients with AML is 40 – 45 % for patient 
younger than 65 years and 15 – 20 % for patient older than 65 years (Ferrara 
and Schiffer 2013). Patient younger than 40 years have 75% to achieve a 
complete remission compared to 68% of patient between 40 and 65 years and 
47% of patient older than 65 years (Mayer, Davis et al. 1994). 
Patients previously treated by chemotherapy can develop AML, known as 
secondary AML or therapy related AML. Several drugs such as 
anthracyclines or epipodophyllotoxins, targeting topoisomerase II, can lead 
to the development of the disease with monocytic abnormalities such as 
translocations involving chromosome bands 11q23 or 21q22 (Godley and 
Larson 2008), and proliferation within months to 2 years of treatment 
(Pollyea, Kohrt et al. 2011). Alkylating agents such as melphalan or 
cyclophosphamide can induce disease with a dose-response relationship. This 
form of treatment related-myelodysplasic syndrome or treatment related 
AML typically occurs within 5–7 years after chemotherapy and/or 
radiotherapy have been given, and confers a poor prognosis (Curtis, Boice et 
al. 1992). The prognosis for AML related to therapy is generally unfavourable 
compared to de novo AML. 
 
Ionizing radiation is another factor that influences the risk of developing 
AML. Studies on the Japanese A-bomb survivors revealed that leukaemia, 
primarily AML, exhibits the highest excess relative risk of all neoplasms 
(Preston, Kusumi et al. 1994). The same conclusions are drawn from a study 
on clean-up workers at the Chernobyl Nuclear Power Plant (Ivanov, Tsyb et 
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al. 1997). Although the risk associated with exposure to lower level radiation 
is not clear, studies have shown an increase in leukaemia following the use of 
radiotherapy. These AMLs induced by radiation were characterized by an 
unfavourable clinical course with resistance to conventional therapy, a shorter 
overall survival and a lower complete remission rate as compared to de novo 
case (Klymenko, Smida et al. 2011). 
Inherited syndromes can also influence the risk of developing AML. Thus, 
children with Down syndrome have a incidence of leukaemia (myeloid and 
lymphoblastic) 10- to 20-fold higher than that in the general population (Fong 
and Brodeur 1987). Other inherited syndromes such as ataxia-telangiectasia, 
Blomm syndrome, Fanconi syndrome increase the risk of leukaemia (Swaen 
1996). 
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Figure 2: overview of haematopoiesis and progenitor cells maturation blockage affected by 
Acute Myeloid Leukaemia (AML) M0 to M7 according the FAB classification and Acute 
Lymphoid Leukaemia (ALL).Common Myeloid Progenitors (CMPs), Granulocyte-
Macrophage Progenitors, Megakaryocyte-Erythroid Progenitors (MEPs), Colony-Forming 
Units (CFUs) for Granulocytes (CFU-Gs), macrophage (CFU-Ms) and megakaryocytes 
(CFU-MKs), Burst  Forming Units Erythrocyte (BFU-E). Adapted from (Krause and Van 
Etten 2007) 
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1.1.4 Acute lymphoblastic leukaemia 
Acute lymphocytic leukaemia affects lymphocyte precursor cells, or 
lymphoblasts that normally become one of three types of lymphocyte, B- and 
T- lymphocyte and natural killer. Leukemic lymphoblasts have an 
uncontrolled expansion, fail to mount a normal immune response and as AML 
cause a drop in production of normal bone marrow cells. The causes of ALL 
development are currently unknown. It appears that chromosomal alterations 
and mutations that are associated with the disease may be inherited from 
pregnancy or develop through infancy and childhood (Pendergrass 1985). 
These chromosomal aberrations can interact with some environmental 
exposures which can lead to some types of ALL (Pendergrass 1985). The 
precursors of T-cell and B-cell can give rise to ALL, however B-cell ALL 
represents about 88% of all cases. ALL represent less than 1% of adult 
cancers, and 25 % of all childhood cancers. It is more frequent in white than 
black and it affects more males than females (Abbasi, Maleha et al. 2013). 
ALL is also the most common form in children, 60% of cases occur in patients 
younger than 20 years (Stanulla and Schrappe 2009). ALL accounting for 
approximately 16% of all childhood leukaemia diagnoses and about 175-200 
children are  diagnosed with ALL each year in the Nordic countries (Norway, 
Denmark, Finland, Iceland and Sweden) (Gustafsson, Kreuger et al. 1998). 
The annual incidence rate in Europe and US is approximately 3.5 per 100,000 
children younger than 15 years old. Before, this disease killed more than 90% 
of its victims within six months. With new drug therapies, more than 80% of 
children with ALL now achieve complete remission, with no evidence of 
malignant cells in the blood. With continued therapy, more than half remain 
free of disease for five years or longer. These patients are presumed to be 
cured.. Treatment related death for this disease is still 2-4% in childhood 
(Lund, Asberg et al. 2011, Rubnitz, Campbell et al. 2013). Infections, 
bleeding or thrombosis, tumour burden complications, and therapy induced 
organ toxicities are the most common causes of therapy related death. 
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1.1.5 Treatment of acute myeloid leukaemia  
Conventional treatment for AML consists of two phases: the induction to 
achieve complete remission and consolidation to eliminate residual leukemic 
blasts after induction. Intensification with or without stem-cell transplantation 
may also be considered.  The induction phase uses interlacing agents, such as 
daunorubicin or idarubicin, that wedge into the spaces between the 
nucleotides in the DNA (Kellogg, Scarsdale et al. 1998) (Figure 3) and 
cytarabin, a pyrimidine analogue that blocks the synthesis of DNA. The 
standard induction phase for adult consists of a combination of an 
anthracycline, usually daunorubicin (DNR), given for 3 days with continuous 
infusion of cytarabine for 7 days (3+7) (Hiddemann, Kern et al. 1999) 
(Ferrara and Schiffer 2013). The induction phase 3+7 induces a complete 
remission rate of 70% for patients younger than 60 years. The use of other 
anthracyclins such as idarubicin, hydrochloride and mitoxantrone, an 
anthracyclin-analog can improve the rate and the quality of complete 
remission (Arlin, Case et al. 1990). The addition of a third drug, usually 
etoposide, at high dose instead of cytarabine can also improve the complete 
remission rate. The induction 3+7 could be repeated if complete remission is 
not observed. 
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Figure 3: Crystal structure of anthracyclines-DNA complex and schematic involvement of 
drug in the dynamics of DNA cleavage by topoisomerase II. Adapted from (Qu, Wan et al. 
2001) 
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The consolidation phase is essential to minimize further relapse after 
induction. A standard consolidation phase consists of several cycles of high 
dose or intermediate dose of cytarabin and/or complete radiation. For 
example, four cycles of high dose cytarabin treatment (3g/m2 every 12h over 
3 days) give a survival advantage in patients up to 60 years old and decrease 
long term relapse. This survival advantage is more striking in patients with 
favourable cytogenetic (Arlin, Case et al. 1990, Wiernik, Banks et al. 1992). 
With consolidation therapy at high dose, patients need hematopoietic stem 
cell transplantation either autologous or allogenic to repopulate the ablated 
bone marrow. Despite the complications of graft-versus-host disease, with a 
treatment mortality of 10-25% (Hiddemann, Kern et al. 1999), a number of 
studies suggest that long-term outcome is improved by allogeneic bone 
marrow transplantation during the first complete remission (Zittoun, Mandelli 
et al. 1995, Cassileth, Harrington et al. 1998). Moreover, the graft versus 
leukaemia effect could have an additional impact with high dose cytarabin. 
In older patients with untreated poor-prognosis leukaemia who can support 
high dose of cytarabin, a reduced treatment combined with allogenic stem cell 
transplantation sufficiently reduces the leukemic burden, resulting in a high 
complete remission through graft versus leukaemia effect (Bertz, Potthoff et 
al. 2003). For an increased rate of complete remission, induction, 
consolidation and stem-cell transplantation treatment are adapted for each 
patient. Major criterias such as the type of leukaemia, cytogenetic, chemo-
resistance leukaemia, patient age and condition, the possibility of allogenic 
transplantation are used to define the appropriate treatment.  
A distinct type of AL, acute promyeolocytic leukaemia (APL), was 
considered the most fatal type of acute leukaemia five decades ago and the 
treatment of APL was a nightmare for physicians due to lack of supportive 
care and cytotoxic-agent-related exacerbated coagulopathy. However, since 
1970, APL benefit from all trans retinoic acid (ATRA) treatment. This 
vitamin A-derivate induces the differentiation of APL blasts and is able to 
induce complete remission. Experience has shown that the combination of 
ATRA and chemotherapy gives better survival in APL than chemotherapy 
alone (fewer relapses and higher complete remission) (Stein and Tallman 
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2014). Maintenance of ATRA treatment in combination with low-dose 
chemotherapy reduces the incidence of relapse. More than 90% of patients 
with newly diagnosed APL can achieve CR and about 75% can be cured by 
the combination of ATRA and chemotherapy (Zhou, Zhang et al. 2007, Sanz, 
Iacoboni et al. 2014). 
 
1.1.6 Treatment of acute lymphoid leukaemia 
Acute lymphoid leukaemia treatment usually stretches from 2 to 2.5 years. 
This includes three phases, remission induction, consolidation and 
maintenance (Pui, Robison et al. 2008). The induction therapy spans 4 to 6 
weeks and is used to reach a complete remission and restores haematopoiesis 
in 96%-99% of children and 78-92% of adults with ALL. Standard regimen 
includes glucocorticoids, such as prednisone or dexamethasone as 
immunosuppressive agents, cytostatic drugs such as vincristine, and 
asparaginase with or without anthracycline. Recently, it was shown that 
patients with BCR-ABL1-positive ALL can benefit from tyrosine kinase 
inhibitors such as imatinib, nilotinib or dasatinib (Inaba, Greaves et al. 2013). 
Consolidation therapy is normally more intense than induction. This phase 
eradicates residual leukemic blast with high-dose of chemotherapy such as 
methotrexate, an inhibitor of DNA synthesis, glucocorticoids and frequent 
pulses of vincristine (Inaba, Greaves et al. 2013). In addition to these drugs, 
patients receive asparaginase during 20-30 weeks uninterrupted. The 
consolidation therapy is a major phase of the protocols. The benefit 
of prolonged use intensive therapy with asparaginase and vincristin treatment 
has been demonstrated for patients with ALL (Pession, Valsecchi et al. 2005). 
Moreover, the intensive treatment improved the outcome of patient with high-
risk disease (Marks, Wang et al. 2010). 
After Consolidation therapy, patients need to have continuation therapy, 
which can stretch from 2 years or more. During this phase, patients received 
antimetabolic drugs, such as mercaptopurine (daily) and/or tioguanine that 
inhibit enzymes involved in purine metabolism (Schmiegelow, Glomstein et 
al. 1997) and methotrexate (weekly) that inhibit folic acid synthesis. 
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Methotrexate can be combined with pulses of vincristine and dexamethasone, 
an immunosuppressive drug.  
As for AML treatment, the hematopoietic stem cell transplantation is 
frequently included in ALL treatment. Allogeneic hematopoietic stem cell 
transplantation has a major role in the management of adults with ALL in first 
or second complete remission. Recent large prospective donor versus no 
donor analyses showed that matched allografting from brother or sister yields 
superior outcomes compared with chemotherapy (Goldstone, Richards et al. 
2008) and its use is recommended in the highest-risk patient. Allogeneic 
transplantation is still the treatment of choice for adults with ALL in second 
complete remission and for children with high risk and/or persistent disease 
where sibling donor allografts yield disease-free survival (Inaba, Greaves et 
al. 2013). Contemporary hematopoietic stem cell transplantation protocols 
with high resolution Human Leucocyte Antigen typing, case-based 
conditioning, and improved supportive care have reduced relapse-related 
mortality, regimen-related toxicity, and infection (Leung, Campana et al. 
2011). 
Chemotherapeutic drugs treatment and stem cell transplantation have 
markedly improved outcome of AL patients. However, there is a remaining 
mortality linked to treatment-related deaths, infection such as pneumonia or 
septicaemia and haemostatic complication. The treatment related death could 
be associated to adverse effects of chemotherapy such as cardio toxicity and 
secondary leukaemia of anthracycline or the graft versus-host disease. Even 
if the intensification of therapy results in an improved overall survival, it is 
associated with increased toxicity (Byrd, Mrozek et al. 2002). Infection is the 
major cause of morbidity and mortality in AL patients and it could be 
associated to neutropenia or to immunosuppression (Jagarlamudi, Kumar et 
al. 2000). However, in the early deaths related to AL, bleeding and thrombosis 
are major risk factors. 
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1.2 Haemostatic disorders associated with acute leukaemia 
 
The development of acute leukaemia may be associated with various co-
morbidities including abnormalities of haemostasis. Bleeding and 
thrombosis, such as haemorrhage, DIC and venous and arterial 
thromboembolism (VTE and ATE), occur frequently in patients with acute 
leukaemia (Falanga and Rickles 2003). The incidence of haemostatic 
complications varies according to the type of leukaemia and the phase of 
treatment. Patients with AML show a rate of haemorrhage of 9.9%, and 1% 
of lethal bleedings occurs during admission day (Ziegler, Sperr et al. 2005). 
Patients with ALL show a rate of non-fatal severe haemorrhages of 3.4%. 
Although thromboembolic disease has been considered less characteristic 
than haemorrhage in patients with AL, several studies are in contradiction 
with this long-held wisdom (De Stefano, Sora et al. 2005, Ziegler, Sperr et al. 
2005). The rates of thrombotic complications for AML and ALL range from 
2.1% to 12.1%. At diagnosis days, 1.4% of ALL patients, 9.6% of AML M3, 
and 3.2% of others AML patients develop thrombotic disease (De Stefano, 
Sora et al. 2005). Among patients with acute myeloblastic leukaemia (AML), 
the incidence of VTE is 5.2%, and among patients with acute lymphoblastic 
leukaemia (ALL), the incidence of VTE is 4.5% in the first two years of 
disease (Ku, White et al. 2009).  
Thrombotic disorders associated with ALL are strongly related to 
chemotherapy. Most of these events occur during remission induction therapy 
(De Stefano, Sora et al. 2005, Grace, Dahlberg et al. 2011). Particularly, L-
asparaginase treatment is associated with an increased risk of developing 
VTE. ATE is also reported but the incidence is less frequent. Thrombosis in 
AML occurs mainly in the first 3 months and could be associated to central 
venous devices and older age. However, the underlying mechanisms of 
thromboembolisms in ALL or AML are not fully understood.  
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1.2.1 Physiopathology of thrombosis in acute leukaemia 
Etiopathology of thrombosis in acute leukaemia is complex and 
multifactorial. Several factors are related to thromboembolism such as 
secondary infections, blood viscosity, hospitalization-related immobility, 
age, central venous device, chemotherapy side effects and prothrombotic 
factor produced by leukemic blasts (Figure 4). 
 
1.2.1.1 Secondary infections 
Neutropenia induced by proliferation of leukemic cells enable bacteria 
develop due to minor immunity response. Bacteria can activate residual 
monocytes, granulocytes and macrophages, which release various cytokines, 
nitric oxide, and tissue factor (TF). These have a direct impact on coagulation 
by the factors XII and VII (Levi 2010). 
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Figure 4. Hypercoagulable state in Leukaemia. Present concept of Virchow’s triad (Kwaan 
2007). 
 
1.2.1.2 Hypercoagulable state  
Hyperleukocytosis induced by AL creates rheological abnormalities that 
leads to slow blood flow and increases blood viscosity in the microcirculation. 
Leukostasis affects the function of brain, eyes, myocardium, lungs and 
kidneys. Microthrombi induced by hyperleukocytosis can spread to larger 
blood vessels and patient can develop venous or arterial thromboembolism. 
Hyperleukocytosis in AL is associated with a very high early mortality rate 
mostly due to respiratory failure or intracranial bleeding (Porcu, Cripe et al. 
2000, Kwaan 2007). The hyper leukocytosis (peripheral blood blasts higher 
than 100,000/µl) complication is more frequent in AML than ALL.  
Age and hospitalization-related immobility also impact on aberrant blood 
flow and lead to a hypercoagulable state. Several studies on thromboembolic 
disease in leukaemia indicate that central venous devices increases the 
incidence of thromboembolism (Freytes 2007). This complication remains an 
important limitation to the delivery of drugs and supportive care to cancer 
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patients. The pathogenesis of catheter-related thrombosis is multifactorial. 
The biocompatibility, the position of the catheter tip, the site of insertion, the 
puncture and thrombophilic abnormalities and catheters-related infections are 
often evoked (Cortelezzi, Moia et al. 2005). However, the vessel damages 
caused by mechanical injury play an important role in the physiopathology.  
 
1.2.1.3 Chemotherapy effects on haemostasis 
Chemotherapy increases the risk of developing thromboembolism. Several 
mechanisms are involved in thrombosis-related therapy.  
Endothelial damages induced by drugs such as daunorubicin or cisplatin-
based chemotherapy, affect coagulation by endothelial cell activation 
(Rickles, Falanga et al. 2007). These drugs enhance phosphatidyl serine 
exposure and the shedding of procoagulant extracellular vesicles (EVs). 
These products from activated endothelial cells directly affect the coagulation 
cascade and promote hypercoagulabe state (Lechner, Kollars et al. 2007, Fu, 
Zhou et al. 2010). ATRA can also effect vessel endothelium. ATRA increases 
the production of cytokines which also affect endothelial cells and induce 
prothrombotic function of endothelial cells (Gerber and Erdman 1981).  
Some chemotherapeutic drugs such as L-asparaginase can also affect 
plasmatic coagulant and anticoagulant proteins by its hepatic toxicity. 
Synthesis of antithrombin, protein C, protein S and plasminogen is impaired 
by L-asparaginase treatment. Cessation of L-asparaginase therapy leads to an 
earlier recovery of the coagulant proteins than anticoagulant proteins. This 
affects the haemostatic balance and generates a hypercoagulable state 
(Mitchell, Sutor et al. 1995). 
Membrane alteration by intercalating drugs such as cisplatin or daunorubicin 
induces monocyte/macrophage prothrombotic phenotype. This phenotype is 
due to the enhancement of TF activity already present on monocyte surface. 
(Walsh, Wheeler et al. 1992). Cisplatin also induces platelet activation and 
aggregation which contribute to vascular and thrombotic complication (Yen, 
Walsh et al. 1993).  
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Finally, the release of leukemic cell cytokines, cancer procoagulant molecules 
and TF in response to chemotherapy may also be important in increasing 
thrombotic risk (Falanga, Consonni et al. 1998). 
 
1.2.1.4 Prothrombotic factor produced by leukemic cells 
Leukemic cells are involved in hypercoagulable state induction by their 
molecular properties. Leukemic blasts can produce and/or express 
procoagulant and fibinolytic factors (Falanga and Rickles 2003, Tallman, 
Lefebvre et al. 2004). Several molecules such as cancer procoagulant cysteine 
protease and TF are found in ALL and AML (Kwaan 2007). In several cancer 
types, tumour cells can shed EVs which express TF and procoagulant 
phospholipids (Tesselaar, Romijn et al. 2007). Several studies suggest an 
important role of EVs derived from cancers cells in the pathogenesis of 
thrombosis (Bharthuar, Khorana et al. 2013, Thaler, Ay et al. 2013, Soff 2014, 
Thaler, Koder et al. 2014). 
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1.3 Extracellular vesicles 
 
Extracellular vesicles are spherical structure limited by a membrane bilayer. 
EVs are used for designating all types of sub-cellular particles in plasma 
(Gould and Raposo 2013). EVs include exosomes and spontaneous- or 
activation- or apoptosis- induced microparticles/ microvesicles (MPs/MVs) 
(Julich, Willms et al. 2014). EVs roughly fall into the size ranges from virus 
(30-100nm) to platelet (1µm-5µm). 
Initially, EVs were considered as waste particles or cellular debris. Currently, 
increasing evidence suggests a major role in many physiological and 
pathological states (Valadi, Ekstrom et al. 2007, Burger, Schock et al. 2013). 
Plasmatic EVs participate in several physiological processes such as 
coagulation, inflammation, cell survival and apoptosis, endothelial function, 
vascular remodelling, and angiogenesis (Bouvy, Gheldof et al. 2014). 
Circulating EVs in blood originate from different cells such as erythrocyte, 
leukocytes, platelets or endothelial cells. Their plasmatic levels result from 
the balance between their rate of release from the cell and their clearance 
(Dasgupta, Abdel-Monem et al. 2009). In healthy subjects, most of circulating 
EVs are originated from platelets and erythrocytes (Arraud, Linares et al. 
2014). Some physiological and pathological conditions are associated with 
changes of the levels and/or the composition of plasmatic EVs (Angelillo-
Scherrer 2012). EVs are implicated in inter cellular communication by 
harbouring or containing ligands, receptors, mRNA and miRNA. These 
molecules allow EVs to modulate biological properties of others cells by 
transfer of membrane protein and exchange of genetic information (Bouvy, 
Gheldof et al. 2014). In this study we mainly focus on cancer EVs and their 
implication in haemostasis by TF and procoagulant phospholipids present at 
EVs surface. 
1.4 Cancer extracellular vesicles procoagulant activity 
 
Some studies have shown that cancer cells –related procoagulant activity (PCA) 
mainly comes from their EVs (Davila, Amirkhosravi et al. 2008). Their PCA is 
linked to exhibition of TF and procoagulant phospholipids such as 
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phosphatidylserine (PS) (Pabinger, Thaler et al. 2013). TF is the major cellular 
initiator of the coagulation cascade that acts synergistically with negative charge 
phospholipids. Cancer cells are well known to express TF and high level of PS. By 
the shedding of EVs, the surface with PS and TF exposure is strongly increased and 
allows the binding of vitamin K-dependent Factors (FVII, FIX, FX and FII). The TF 
at EVs surface can cleave the FVII/VIIa and form an active complex which can 
activate the FX in FXa and leads to active thrombin formation (Figure 5) (Kasthuri, 
Taubman et al. 2009, Zwicker, Liebman et al. 2009).  
Accumulating evidence suggests that circulating TF-bearing EVs may play 
important roles in venous thrombosis related to cancer due to the expression of TF 
by cancer cells (Davila, Amirkhosravi et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Activation of coagulation cascade by EVs derived from cells. Activated TF and 
procoagulant phospholipids on EVs surface activates tissue factor pathway of coagulation 
cascade. Complex TF-factor VII activates factor X which activates prothrombin. These 
activations need negatively charged phospholipids (PLs) and Ca++. Tissue factor pathway 
inhibitor (TFPI) is present in plasma and inhibits the complex TF/FVIIa/FXa.  
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2 Aims of the study 
 
The early death of leukemic patient by thrombosis complication is still a 
major public health problem. Because of their hematopoietic disorder, their 
frequent thrombocytopenia and their risk of bleeding, we need to clearly 
understand the pathophysiology and underlying mechanisms of thrombosis in 
these patients. From a clinical perspective, it would be extremely helpful to 
identify and validate biomarkers that enable the early identification of cancer 
patients at risk of VTE and to target anticoagulation for primary prevention 
of VTE based on risk stratification. This reliable diagnosis should go through 
a clear understanding of the pathological mechanisms of thrombosis in 
leukemic patients. 
The aim of our work is to investigate the hypercoagulable state in leukemic 
patient responsible of thromboembolic disease development. The primary 
objective is to characterize the prothrombotic role of plasmatic procoagulant 
extracellular vesicles. The secondary objective is to validate the use of EVs 
as potential biomarker to identify patient with high risk of thrombosis. 
To reach this objective, we first developed several technics to study the EVs 
in vivo and in vitro. We then investigated if leukemic cells can shed 
procoagulant EVs and the impact of intercalating agents on EVs procoagulant 
activity. Finally, we studied the EVs PCA from patient plasma samples and 
compared this activity with clinical data 
The aims of the present thesis were: 
1) To evaluate the combination of thrombin generation assay, 
transmission electron microscopy and flow cytometry to study tissue 
factor bearing EVs from breast cancer cells. Breast cancer cells are 
well known to produce prothrombotic EVs with TF. 
2) To increase the sensitivity of thrombin generation for detection of 
plasmatic PCA of EVs. 
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3) To assess the role of EVs derived from acute promyelocytic leukemia 
cells in the activation of coagulation cascade and the effect of DNR 
on EVs PCA. 
4) To evaluate PCA of EVs from acute leukemic patient as biomarker in 
thrombotic event in acute leukemic patients. 
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3 Development of methods  to study cancer extracellular 
vesicles procoagulant activity 
 
Original article in Journal of extracellular vesicles: 
Thrombin generation assay and transmission electron microscopy: a 
useful combination to study tissue factor-bearing microvesicles. 
 
Damien Gheldof, Julie Hardij, Francesca Cecchet, Bernard Chatelain, Jean-
Michel Dogné*, François Mullier*. 
 
Several techniques have been described to study EVs (van der Pol, Hoekstra 
et al. 2010). In order to provide a complete EVs characterization, we need to 
combine different techniques. In this paper we work with different 
techniques. Thrombin generation assay gives an overview of PCA and the 
origin (TF or PLs) of PCA can be determined by using antibody against TF 
or Annexin V. Flow cytometry gives a count of EVs and allows to detect 
specific molecules on their surface. And transmission electron microscopy 
permits a precise size determination. To study the combination of these 
techniques, we work with a well know model in cancer derived EVs with 
PCA linked to TF, the breast cancer cell lines MDA-MB-231.(Davila, 
Amirkhosravi et al. 2008). 
This study provides a characterization of cell-derived EVs, validates the 
sensitivity and intra/inter assay variability of TGA and provides a 
combination of techniques to study procoagulant EVs derived from cancer 
cells. 
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3.1 Abstract 
 
INTRODUCTION: Patients with cancer have a 7- to 10- fold increased risk 
of developing venous thromboembolism. Circulating microvesicles could be 
a useful predictive biomarker for venous thromboembolism in cancer. 
Validated and standardized techniques that could be used to determine the 
complete microvesicle phenotype are required. 
MAIN OBJECTIVES: i) to characterize tissue factor (TF) bearing 
microvesicles released by cultured breast cancer cells MDA-MB-231 by flow 
cytometry (FCM), transmission electron microscopy (TEM) and thrombin 
generation assay (TGA) ii) to validate the sensitivity and variability intra/inter 
assay of TGA as a useful method to study the procoagulant activity (PCA) of 
microvesicles. 
METHODS: Cultured breast cancer cells MDA-MB-231 were incubated for 
45 min at 37°C. 
Samples were then centrifuged or not at 4,500g for 15 min and cells and MVs 
or MV-containing supernatants were used for TEM, FCM and TGA. In 
activity assays, microvesicles (i.e. cell-depleted supernatants) were incubated 
with anti-TF antibodies or with annexin V to assess the contribution of TF 
and phospholipids to the procoagulant activity (PCA). Alternatively, 
supernatants were filtered through 0.1, 0.22, 0.45 or 0.65μm membranes and 
subjected to TGA. 
RESULTS: The majority of the PCA was associated with microvesicles 
smaller than 0.1 μm, and the mean microvesicle size estimated by TEM after 
10,000 g centrifugation was 121+/-54 nm with a majority of vesicles between 
100 and 200 nm. Microvesicles derived from 5,000 MDA-MB-231cells/ml 
were sufficient to significantly increase the thrombin generation of normal 
pooled plasma.  
CONCLUSIONS: TEM, FCM and filtration coupled to TGA represent a 
useful combination to study the PCA of TF-bearing microvesicles, whatever 
their size. And it will be interesting to implement these techniques in patients.  
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Abbreviations: Venous thromboembolism: VTE; Microvesicles: MVs; 
Tissue factor: TF; Flow cytometry: FCM; Transmission Electron 
Microscopy: TEM; Thrombin Generation Assay: TGA; TFPI: Tissue Factor 
Pathway Inhibitor; Normal pooled plasma: NPP; Microparticles: MPs; 
Phospholipid(s): PLs; Procoagulant activity: PCA; Phosphate buffer saline: 
PBS; Standard deviation: SD; Antibody: Ab; Supernatant: Sup; Filtrate: Filt; 
Monoclonal antibodies: mAbs; TF bearing Microvesicle: TF-MV 
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3.2 Introduction 
 
Venous thromboembolism (VTE) is responsible for 15% of deaths in cancer 
patients (Manly, Wang et al. 2010, Noble and Pasi 2010, Gerotziafas, Galea 
et al. 2011). Therefore, thromboprophylaxis for hospitalized cancer patients 
is recommended (Khorana, Kuderer et al. 2008). However, individual risk 
factors cannot identify a group of outpatients at highest risk for VTE that 
would benefit from thromboprophylaxis (Khorana, Kuderer et al. 2008). 
Several studies strongly suggest that microvesicles (MVs) harbouring tissue 
factor (TF-MVs) activity may have prognostic value in identifying cancer 
patients with increased risk of VTE (Owens and Mackman 2011). MVs are 
small membrane vesicles shed by most normal and/or tumour cells 
constitutively or following activation or apoptosis (Kasthuri, Taubman et al. 
2009, Zwicker, Liebman et al. 2009). Based on the size and mechanism of 
synthesis, MVs are currently divided into exosomes and microparticles (MPs) 
(van der Pol, Hoekstra et al. 2010). The diameter of exosomes is comprised 
between 30 and 100 nm whereas MPs have a size comprised between 100 nm 
and 1 μm. However, this definition is not generally accepted due to 
technological limitations in size measurement (van der Pol, Hoekstra et al. 
2010). MVs may present TF and negatively charged phospholipids (PL) such 
as the phosphatidylserine on their membrane. These elements are thought to 
be implicated in the procoagulant activity (PCA) (Freyssinet and Toti 2010). 
In several types of cancers, including breast and pancreatic cancers, TF 
expression is associated with a prothrombotic phenotype and correlates with 
grade and tumour progression (Kasthuri, Taubman et al. 2009, Zwicker, 
Liebman et al. 2009, Zwicker 2010). The TF is present in plasma under two 
major forms: a full-length TF that may be anchored at MVs surface (TF-MVs) 
or an alternative spliced soluble protein. TF associated with MVs is 
considered as the main form exhibiting PCA (Davila, Amirkhosravi et al. 
2008, Mackman 2009, Manly, Wang et al. 2010). MVs are defined by size, 
concentration, morphology, biochemical composition, cellular origin and 
activity. Numerous techniques have been described to detect and/or 
characterize the MVs (van der Pol, Hoekstra et al. 2010). However, no 
technique is able to provide all MV characteristics. Consequently, the 
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combination of different techniques is required for a complete description of 
MVs (Freyssinet and Toti 2010).  For example, flow cytometry (FCM), which 
is the most used technique to study MVs, suffers from a lack of sensitivity to 
small-sized MVs and gives no information about the TF and/or 
phopspholipid-mediated procoagulant activity. Thrombin generation assay 
(TGA) can be used to specifically assess the impact of TF-MV on 
coagulation. However, this technique is limited by absence of standardization 
and by the unknown sensitivity to low levels of TF due to presence of Tissue 
Factor Pathway inhibitor (TFPI) in plasma (Dargaud and Negrier 2010, Key 
and Mackman 2010).  
It is therefore essential to validate and standardize a panel of techniques that 
could be used to determine the complete MVs phenotype and to study the 
effects of preanalytical steps on MVs’ conformation (potential fragmentation 
or aggregation). 
The objectives of this study were therefore i) to characterize tumour cell-
derived MVs released by cultured MDA-MB-231 breast cancer cells with 
FCM, Transmission Electron Microscopy (TEM) and TGA and ii) to validate 
the intra/inter assay sensitivity and variability of TGA as a useful method to 
analyse MVs PCA 
 
3.3 Material and methods 
 
3.3.1 Cell culture  
Adherent MDA-MB-231 breast cancer cells (ATCC number HTB-26) were 
obtained from the American Type Culture Collection (Manassas, VA, USA) 
and were cultured in RPMI-1640 medium (Lonza, Verviers, Belgium) 
supplemented with 10% fetal bovine serum (FBS) (Lonza, Verviers, 
Belgium). Cells were maintained in a 5% CO2 humidified atmosphere at 
37°C. Natrium bicarbonate was set at 1.5g/L to control the pH. Cell viability 
was controlled by the trypan blue exclusion test. 
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3.3.2 Preparation of normal-pooled plasma and platelet-free plasma 
Normal pooled-plasma (NPP) was prepared as previously described (Robert, 
Ghiotto et al. 2009). Platelet-free plasma was obtained by a first 
centrifugation once at 2,500g for 15min at room temperature (Heraeus 
Multifuge 1S-R, Sysmex Benelux, Etten-Leur, The Netherlands) with a light 
brake only, within one hour after sampling. The platelet-poor plasma was 
collected and transferred into a polypropylene haemolysis tube with a 
micropipette. Aspiration was stopped 1cm above the buffy-coat while 
avoiding the buffy-coat. Platelet-poor plasma was centrifuged a second time 
at 2,500g for 15 min at room temperature. The platelet-free plasma was 
collected into a fresh tube using a micropipette, while leaving about 100μl at 
the bottom of the tube.  
3.3.3 In vitro generation of MVs 
A modified version of the protocol reported by Davila et al. was performed 
(Davila, Amirkhosravi et al. 2008). Cells were adjusted to the desired 
concentrations (600,000 cells/ml for TGA and TEM) in PBS and then 
incubated for 45 min at 37°C without any stirring. Samples were then 
centrifuged or not at 4,500g for 15 min (Figure 6). Afterwards, cells and MVs 
or fresh MV-containing supernatants devoid of cells were used for TEM, 
FCM and TGA. PBS was used as negative control. 
3.3.4 Preparation of samples for TEM observation:  Tumor MVs 
visualisation and sizing by TEM 
One ml of PBS containing 600,000 MDA-MB-231 cells and their secreted 
MVs was centrifuged at 10,000g for 90 min at 4°C to form a pellet (Figure 
6). The pellet was fixed for TEM observation during 2.5 hours in 300 µl of 
2.5 % glutaraldehyde in 0.1 M cacodylate buffer. Samples were then washed 
using 0.2 M cacodylate buffer. Osmium tetraoxide was added during 1 hour 
as contrasting agent. Samples were further washed with 0.2 M cacodylate 
buffer and dehydrated with successive baths of alcohol from 30° to 100°. 
Impregnation of samples in resin LX 112 was then done. After resin 
polymerization, samples were cut with an ultra-microtome (LKB, Bromma 
8800®), mounted on a grid and stained with heavy metal salts (uranyl acetate 
and lead citrate). The samples were observed using Tecnai 10 TEM (FEI, 
Eindhoven, The Netherlands; resolution of about 5 nm at 80 kV). The MV 
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size determination was performed semi-automatically on high magnification 
TEM pictures (Figure 7B) with the Image J software (Maryland, USA). One 
hundred MVs were sized (Serda, Godin et al.). The result was expressed as 
mean ± S.D with range in parentheses. 
3.3.5 Counting and expression of TF and MUC-1 by flow cytometry 
Quantification of MVs and expressions of TF and Mucin-1 (MUC-1) on 
MDA-MB-231 cells and MVs were carried out by FCM as mentioned in 
supplementary information. MUC-1 was chosen since it has been shown that 
TF-MV activity of patients with breast cancer who presented with acute VTE, 
correlated with the presence in the blood of MV expressing the epithelial 
antigen MUC1 (Tesselaar, Romijn et al. 2007). 
3.3.6 Measurement of the MVs procoagulant activity (PCA) by thrombin 
generation assay 
PCA was measured by TGA according to a modified version of the method 
developed by Hemker (Hemker, Giesen et al. 2002). Total cell suspensions 
or cell-depleted in vitro-generated MV fractions from 600,000 cells/ml were 
used as the source of TF and phospholipids. 80 µl of Normal Pooled Plasma 
(NPP) and 20µl of cell suspensions or MV fractions were mixed in a 96-well 
microtiter plate (Thermo Immulon 2HB, USA) and were incubated for 10 min 
at 37◦C. PBS was used as a negative control. Early experiments are tested 
with or without addition of 20µl of MP reagent, which correspond to 4µM of 
phospholipids (Thrombinoscope BV). The detailed protocol has been 
described elsewhere (Robert, Ghiotto et al. 2009). 
All the experiments were performed in triplicate. The results were expressed 
as means ± S.D. All parameters were calculated using software 
thrombinoscope. The % of PCA was calculated on the lagtime reduction by 
MVs. 
Variability of TGA was measured according to the previously described 
method using 80 µL of NPP + 20 µL PBS. The assays were conducted in 
triplicate on six independent runs with the same operator.  Mean intra-assay 
variation and inter-assay variability for lagtime and peak were determined. 
Mean intra-assay variation corresponds to the mean coefficient of variation 
for the triplicates (n=6). Inter-assay variation corresponds to the coefficient 
of variation for the mean value of triplicates between the 6 independent runs.  
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3.3.7 Effect of MVs size on PCA 
MV fractions were filtered through 0.1, 0.22, 0.45 or 0.65 µm membranes 
(Ultrafree-MC; Amicon, Bedford, MA, USA) following the manufacturer’s 
instructions. Supernatant (Sup) and filtrates (Filt) were compared by TGA 
and FCM (1 experiment in triplicate). 
3.3.8 Contribution of TF and phospholipids to MVs PCA 
For contribution of TF, MVs derived from 600,000 cells/ml were pre-
incubated with various monoclonal antibodies (mAbs) (10µg/ml, optimal 
final concentration) for 20 min at room temperature before TGA was 
performed.  
The clone HTF-1 (BD Biosciences, Erembodegem, Belgium) was used as TF-
activity neutralizing Ab (Wang, Manly et al. 2009). The clone TF9-10H10 
(Merck, Darmstadt, Germany) and IgG1 (BD Biosciences, Erembodegem, 
Belgium) were tested as a non-function-blocking antibody (Gessler, Voss et 
al. 2010) and isotypic control antibody, respectively.  
The phospholipid-mediated activity was blocked with annexin V (Sigma-
aldrich, Bornem, Belgium) (Peng, Jiang et al. 2001). Samples were pre-
incubated with annexin V (0.5 µM, final concentration) for 20 min at room 
temperature before TGA was performed (Davila, Amirkhosravi et al. 2008). 
Three independent experiments were performed in triplicate. 
3.3.9 Effect of ultracentrifugation on PCA 
MV derived from 100,000 cells/ml were separated from the cells by 
centrifugation at 4,500 g during 15 min. The collected supernatants, which 
contain only MVs, were ultracentrifuged at 100,000g during 90 min to pellet 
the MVs. MV before ultracentrifugation (Sup), pellet of MVs (Pellet UC) and 
supernatant after ultracentrifugation (Sup UC) were tested in TGA. 
3.3.10 Effect of stirring and centrifugation on MV PCA 
The standard protocol described above for the in vitro generation of MVs is 
described in Figure 6. In preliminary experiments, our standard protocol 
without stirring was compared to that proposed by Davila (Davila, 
Amirkhosravi et al. 2008) which includes stirring (at 1,000 rpm) on 
aggregometer during the 45 min of cell incubation in PBS. The cell 
supernatants were used for TGA. 
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Three centrifugation protocols to eliminate cells were also compared using 
TGA at 600,000 cells/ml: I) simple centrifugation at 4,500 g for 15 min 
(Davila, Amirkhosravi et al. 2008), II) double centrifugation at 2,500 g for 15 
min and III) double centrifugation: at 1,500 g for 15 min and at 13,000 g for 
2 min. Three independent experiments were performed in triplicate. 
3.3.11 Effect of cell concentration on MVs PCA 
To determine the sensitivity of TGA, the impact of cell concentration on TGA 
was assessed at 100; 500; 1,000; 2,500; 5,000; 10,000 and 20,000 cells/ml. 
Three independent experiments were performed in triplicate. 
3.3.12 Statistics 
Comparison between different conditions was performed using the Kruskal-
Wallis test on Medcalc software (version 12.2.1.0). If the Kruskal-Wallis test 
is positive (P<0.05) then MedCalc performs a test for pairwise comparison of 
subgroups according to Conover, 1999. Conover WJ (1999) Practical 
nonparametric statistics 3rd edition. New York: John Wiley & Sons. 
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Figure 6. Sample preparation. All supernatants were freshly used for TEM, FCM and TGA. 
PBS: Phosphate Buffer Saline. Sup: Supernatant. Filt: Filtrate. UC: ultracentrifugation 
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3.4 Results 
 
3.4.1 Characterization of MVs derived from MDA-MB-231 cells 
The different experimental settings used in this work are schematized in 
Figure 6. Images of MDA-MB-231 cells with TEM after 10,000 g 
centrifugation showed that these tumor cells spontaneously shed small MVs 
from their membrane (Figure 7). The MVs mean size after centrifugation of 
the cells and MVs, was 121± 54 nm [range: 57 nm to 440 nm].  The size 
distribution was not statistically different when we ultracentrifuged cells with 
MVs at 100,000g. However, we cannot provide a picture of MVs after 
ultracentrifugation because of the insufficient amount of the pellets. 
Concerning their membrane protein surface expression, MDA-MB-231 cells 
were strongly positive for both MUC-1 (= CD227) and TF (= CD142). 10% 
of all MVs were positive for TF expression, and only 1.7% were positive for 
MUC1 (Figure 8). The final MVs concentration in “MDA” samples (cells 
and MVs) was 1,199 MVs/µl (Table 1).  
 
 
 
 
Figure 7. Transmission electron microscopy pictures of cells with derived MVs (white 
arrows) after ultracentrifugation at 10,000 g during 90 minutes. A) Scale bar 2 µm. N: nucleus 
C: cytoplasm; B) scale bar 500 nm; C) scale bar 2 µm. 
  
   A) 
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Figure 8. Expression of TF (CD142) and MUC-1 (CD227) on MVs depleted of cells. A) 
Tumor microparticle analysis. Dual fluorescence analysis of MDA-MB-231 MVs stained 
with CD227 fluorescein isothiocyanate (FITC) (FL1) and CD142–phycoerythrin (PE) (FL2). 
CD142+ CD227+ MVs are represented as green dots, CD142+ CD227- MVs as red dots, 
CD227+ CD142- MVs as blue dots and background noise or other MVs as orange dots. 
Percentage and absolute number (/µl) of each subpopulation are indicated.  B) Backgating of 
CD142+ CD227+ MVs (green dots), CD142+ CD227- MVs (red dots) and CD227+ CD142- 
MVs (blue dots) on FSC log-SSC log cytogram. C) Expression of TF (CD142) and MUC-1 
(CD227) on PBS without MVs. D) FSC-SSC of control PBS without MVs labelled similarly 
with CD142 and CD227. E) FSC-SSC dot plot of 500 and 900nm beads used to gate on MVs. 
 
 
Sample 
MVs MUC-
1+/TF- (/µl) 
MVs MUC-1-
/TF+ (/µl) 
MVs MUC-
1+/TF+ (/µl) 
Cells 86 1014 99 
Sup 44 60 30 
Sup, St 39 128 15 
Sup Filt 0.65µm  47 25 15 
Sup Filt 0.45µm  48 21 17 
PBS 0 0 0 
 
Table 1. Flow cytometry concentration of MVs MUC-1+/TF-, MVs MUC-1-/TF+ and MVs 
MUC-1+/TF+ (/μl) in : cells and MPs (Cells), MDA-MB-231 supernatant (Sup), MDA-MB-
231 supernatant produced with stirring (Sup, St), Sup filtered through 0.65µm and 0,45 µm 
membranes (Sup Filt 0,65µm  and Sup Filt 0,45 µm) and PBS as control. 
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3.4.2 Procoagulant activity of MDA-MB-231 cells-derived MVs 
MDA-MB-231 cells and their derived MVs (“MDA” sample) significantly 
boosted up the generation of active thrombin when compared to the PBS 
control curve (Figure 9A), as shown by the 10-fold reduction of lagtime. 
MDA-MB-231 supernatant (“Sup MDA” sample), which only contains MVs, 
also enhanced thrombin activity compared to the control as indicated by the 
9-fold lagtime reduction. The difference between MDA-MB-231 cells and 
their supernatant was highly significant for both lagtime (P-value = 0.0091) 
and peak (P-value = 0.0039). FCM analysis showed a 10-fold decrease in 
TF+-MVs concentration between MDA and Sup MDA samples (Table 1, 
1113 versus 90/µl), suggesting that the majority of MVs detected by flow 
cytometry carrying PCA activity remain associated to the cell surface and co-
pellet with the cells after centrifugation at 4,500g. These data are consistent 
with the reduction of PCA between these samples. 
Since FCM cannot detect vesicles smaller than 300 nm, and since TEM 
showed a majority of MVs smaller than 300 nm, the link between the MVs 
size and procoagulant activity was evaluated through filtration of the 
supernatant using membranes with various cut-off sizes ranging from 0.65 to 
0.1 µm (Figure 9B). As compared to the initial supernatant (“Sup MDA”), 
which displayed a 9-fold reduction in lagtime, the 0.65µm- or 0.45 µm- 
filtered supernatant (“Sup MDA Filt 0.65µm” or 0.45 µm respectively) 
displayed a slightly reduced PCA, shown by a 7-fold reduction in lagtime 
when compared to the control. The difference between samples before and 
after the 0.65 or 0.45µm filtration was highly significant both for lagtime and 
for the peak parameter. These data are supported by FCM as filtration at 0.65 
or 0.45 µm reduced by two-fold the number of TF+ MVs as compared to non-
filtered supernatant (40 or 38 respectively, as compared to 90 / µl) (Table 1). 
Finally, lagtime was increased 2.2- and 2.5-fold after filtration through 0.22 
and 0.1µm, respectively, in comparison to unfiltered supernatant, but was still 
4- and 3.6-fold reduced as compared to PBS. These analyses were performed 
without “MP reagent”, however the same observations were made with or 
without addition of phospholipids. We conclude that TF-MVs of different 
sizes participate in PCA activity, those larger than 0.65 µm displaying 
proportionally less activity than the MVs retained by 0.22 and 0.1 µm filters, 
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and that the majority of the PCA was associated with components smaller 
than 0.1 µm.  
The use of “HTF-1”, an anti-TF antibody, was associated with a strong 
inhibition of the PCA associated to MVs as revealed by a 6-fold increase in 
lagtime (Figure 9C). On the other hand, the PCA was not affected by a non-
blocking antibody (TF9-10H10), nor by an isotypic control (IgG1). These 
data confirm the specificity of PCA inhibition by the anti-TF antibody. 
Inclusion of annexin V during the assay was associated with a complete 
abolishment of PCA (Figure 9D).  
The majority of PCA contained in supernatant was associated with the pellet 
after 100,000 g ultracentrifugation, but some activity remained in the post-
ultracentrifugation supernatant (Figure 9E): this supernatant still reduced 
lagtime 2.5-fold in comparison to normal pooled plasma spiked with PBS, 
however it showed no significant increase of peak of active thrombin (Figure 
9E). 
The lagtime and peak intra-assay variation coefficients were 12% and 11%, 
respectively. The lagtime and peak inter-assay variation coefficients were 
14% and 50%, respectively. 
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Figure 9. Curves of thrombin generation experiments and histograms of lagtime and peak 
parameters. In control condition, NPP is spiked with PBS. Curve data are presented as means 
of n=3. All the results are representative of 3 independent experiments. A) NPP spiked with 
MDA-MB-231 cells (Cells) or supernatant from MDA-MB-231 cells (Sup). The supernatant 
shows only slightly reduced PCA as compared to cell + supernatant. B) NPP spiked with 
supernatant from MDA-MB-231 cells (Sup), filtered or not through membranes with various 
sizes (Sup Filt 0.1µm/0.22µm/0.45µm/0.65µm). Filtration through 0.65 or 0.45 µm reduces 
only slightly the PCA, whereas filtration through 0.22 and 0.1 µm leads to stronger reduction 
in PCA. C) Procoagulant effect of MVs (Sup) pre-incubated with or without HTF-1 (TF-
blocking Ab), TF9-10H10 ((TF-non blocking Ab) or isotypic control antibodies at 10µg/ml. 
HTF-1 strongly inhibits PCA of MV-containing supernatant. D) Procoagulant effect of MVs 
(Sup) pre-incubated with or without annexin V at 0.5 µM. AnnexinV abolishes the PCA 
activity of the MV-containing supernatant. E) Procoagulant effect of MVs derived from 
100,000 cells (Sup), of the pellet obtained after ultracentrifugation of MVs (pellet UC Sup) 
and of the supernatant obtained after ultracentrifugation of MVs (Sup UC). 
3.4.3 Influence of stirring and centrifugation on PCA of MDA-MB-231 
cells and MVs 
The stirring of MDA-MB-231 cells during MVs generation does not modify 
the PCA of cells (“Cells”) and MVs (“Sup”) derived from 600,000 cells/ml 
(Figure 10A). However, FCM analysis showed a difference between MVs 
concentration in samples stirred or not (Table 1). 
The centrifugation protocol used to separate cells and MVs does not 
significantly impact TGA curves (Figure 10B). Indeed, curves are very 
similar both for the supernatant and the 0.1µm-filtered supernatant generated 
from 600,000 MDA-MB-231 cells/ml, using either one of protocols I, II or 
III described in Figure 6.  
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Figure 10. Effect of stirring during cell incubation and of cell centrifugation protocol on 
thrombin generation. A) Thrombin generation curves and histograms of lagtime and peak 
parameters of Normal Pool Plasma (PBS) spiked with MDA-MB-231 cells stirred (Cells, st) 
or not (Cells) or with their respective supernatant (Sup, st and Sup). No difference in PCA is 
observed between the stirred and non-stirred samples. B) Thrombin generation curves and 
histograms of lagtime and peak parameters of Normal Pool Plasma spiked with supernatant 
of cells filtered or not (Sup vs. Sup Filt 0,1 µm) and produced by three different centrifugation 
protocols (Sup I, II, III). In control wells, NPP is spiked with PBS. The curve is representative 
of 3 independent experiments.  
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3.4.4 Sensitivity of TGA 
As shown in Figure 11, a dose-response relationship is observed from 100 to 
20,000 cells/ml for both MDA-MB-231 cells and MVs. A threshold 
concentration of 500 MDA-MB-231 cells/ml is sufficient to release enough 
TF-MVs that significantly reduce the lagtime in comparison to control (P-
value = 0.034). When the supernatant is considered, 5,000 MDA-MB-231 
cells/ml is the threshold concentration required to significantly reduce the 
lagtime (P-value = 0.034). The coefficients of variation for Lagtime, ETP, 
Peak and Ttpeak were 12%, 11%, 11% and 9% in intra-assays (n=6) and 14%, 
34%, 50% and 16% in inter-assay (n=6), respectively.   
 
 
 
 
 
 
 
Figure 11. Procoagulant effect of cells (Cells, A) and MVs (Sup, B) derived from different 
MDA-MB-231 cell concentrations (0-100-500-1,000-2,500-5,000-10,000-20,000-cells/ml) 
on lagtime. In control wells, NPP is spiked with PBS. Results are presented as mean +/- SD. 
Data with significant difference in comparison to control are indicated with * (p<0.05). 
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3.5 Discussion  
 
VTE prophylaxis during systemic chemotherapy is not recommended for 
ambulatory patients with cancer (Khorana, Streiff et al. 2009). Indeed, there 
is currently no validated biomarker presenting a thrombotic profile able to 
lead to an adapted prophylaxis (Khorana, Kuderer et al. 2008). The circulation 
of active TF associated with MVs has been considered as a promising and 
interesting biomarker to prevent VTE in cancer (Manly, Wang et al. 2010, 
Zwicker 2010, Owens and Mackman 2011). An ongoing phase III study 
(MicroTEC, NCT00908960) in advanced cancer patients with high levels of 
TF bearing MVs has been designed to evaluate the benefit of primary 
thromboprophylaxis and to validate the prognostic usefulness of measuring 
TF bearing MVs (Zwicker, Liebman et al. 2009). However, validation and 
standardization of techniques measuring TF-MVs are required before 
considering cut-off values of this biomarker in risk-stratification approaches. 
In this study, we compared results obtained with TEM, FCM and TGA to 
determine the size, the concentration and the PCA of tumour MVs. We used 
the well-established invasive/metastatic MDA-MB-231 breast carcinoma cell 
line, which is known to express high levels of TF (Davila, Amirkhosravi et 
al. 2008). By FCM, we highlighted that the majority of cells and 10% of cell 
derived-MVs are positive for TF, and only a few microvesicles express MUC-
1 (Figure 8). MUC-1 was chosen since it has been shown that TF-MV activity 
of patients with breast cancer who presented with acute VTE, correlated with 
the presence in the blood of MVs expressing the epithelial antigen MUC1 
(Tesselaar, Romijn et al. 2007). Moreover, FCM allows determining 
TF+MVs or MUC-1+MVs concentrations. However, FCM suffers from a 
lack of sensitivity to small-sized MVs (i.e. MVs-size < 0.5µm) (van der Pol, 
Hoekstra et al. 2010) and it has been recently shown that microvesicle 
detection by flow cytometry is attributed to both large single vesicles and 
swarm detection of smaller vesicles (van der Pol, van Gemert et al. 2012, 
Alain R. Brisson, Sisareuth Tan et al. 2013) . Therefore, data presented in 
Table 1 can represent both large vesicles and aggregates of small 
microvesicles. Although new tools using size-calibrated beads and recent 
progress in instrumentation may improve detection of MVs populations of 
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smaller sizes, flow cytometry is the only validated technique available for 
MV quantification. However, unless recent improvements, FCM is only 
suitable for large microvesicles.(Lacroix, Robert et al. 2010, van der Pol, 
Hoekstra et al. 2010), Thus FCM will not allow the detection of smallest MVs 
and does not give any information about their TF-mediated PCA.  
Using TEM, we showed that there is a budding of MVs on cell surface, these 
results are in agreement with previous study on MV formation and show that 
MV constitution can be directly linked to the cell surface membrane. 
However, for vesicles away from cells, we cannot determine whether they 
bud off the cell membrane or whether they were released by another means. 
Moreover, by TEM, we showed that size of MDA-MB-231-derived MVs 
ranges from 0.05 µm to 0.45 µm in diameter, the majority of MVs is 
comprised between 0.1µm and 0.2µm and 36% of MVs  is comprised under 
100nm These results are in agreement with those of Xiong (Xiong, Aras et al. 
2003). However, as slices are performed, these measures may be 
underestimated as the vesicles are not always cut in their equator. On the other 
hand, as observed with manufactured nanoparticles (Tenzer, Docter et al. 
2011), MVs may associate with proteins (“corona effect”) during TEM 
preparation leading to a overestimation of the size. Cryoelectron microscopy 
may represent an interesting alternative to view every MV in natural 
condition (Buzhynskyy, Golczak et al. 2009).   
We also validated TGA to characterize the PCA of MVs. In agreement with 
FCM data, we confirmed that the PCA of MDA-MB-231 cells, is mainly due 
to MVs release. The higher PCA observed for MDA-MB-231 cells compared 
to their supernatant mostly resulted from a loss of the largest MVs or MVs 
aggregates by centrifugation, as shown by the differences in MVs 
concentration between cells and supernatant determined by FCM. However, 
our study confirmed that MDA-MB-231 cells could also support PCA 
(Berny-Lang, Aslan et al. 2011). Surprisingly, we also showed that the 74% 
of TF-activity is associated with particles smaller than 0.1 µm even if only 
36% of MVs visualized by TEM are smaller than 0.1 µm. The filtration 
experiments also show that about 8 % of activity is associated with vesicles 
larger than 0.65 µm, vesicles of sizes comprised between 100 and 650 nm 
display 20% of MVs PCA. Thus very small vesicles display a high PCA.  
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By using an anti-TF function-blocking antibody (HTF-1) and annexin V 
which links phosphatidylserine, we confirmed that the PCA of MVs is related 
to the expression of active TF and negatively charged PL (Butenas, Bouchard 
et al. 2005). Moreover annexin V block phospholipids from MVs contained 
in the NPP. The anionic phospholipids are required for initiation and 
propagation of TF-dependent coagulation. It seems therefore likely that only 
TF bound in negative phospholipids membrane will support thrombin 
formation. This result confirms that the active form of TF mainly comes from 
MVs. It has been extensively reported that the presence of TF on the cell 
surface does not necessarily correlate with TF activity. Indeed, the majority 
of membrane-anchored TF molecules would be in a non-active encrypted 
conformation and "decryption" would thus be essential for the expression of 
TF function (Butenas, Parhami-Seren et al. 2009). The difference in peak 
between supernatant of MDA-MB-231 cells and MVs can be explained by 
the phospholipids provided by tumour cells (Tesselaar, Romijn et al. 2007, 
Davila, Amirkhosravi et al. 2008).  
Because the clinical importance of MVs is increasingly being recognized, it 
is crucial to standardize methods to allow comparison of data across different 
studies. To validate the use of TGA for measuring the PCA of MVs, we 
assessed the impact of two pre-analytical variables, i.e. stirring and 
centrifugation, and determined the sensitivity of this technique. Contrary to a 
previous report (Davila, Amirkhosravi et al. 2008), the stirring of cells did not 
increase the production of MVs, as shown by MV counting by FCM and 
above all, by PCA measurement. In addition, no significant differences 
between the three centrifugation protocols were observed in TGA which is 
compatible with the small size of MVs released by MDA-MB-231. Moreover, 
ultracentrifugation did not allow abolishing completely the PCA, which is in 
contradiction with Davila et al.(Davila, Amirkhosravi et al. 2008). One 
hypothesis is that some small TF-MVs may not be pelleted with 
ultracentrifugation at 100,000g, and may require higher speed or longer time 
of centrifugation. Another explanation can come from the cells’ release of 
active soluble tissue factor (Kocaturk and Versteeg 2012). Finally, 5,000 
MDA-MB-231 cells/ml are sufficient to detect a lagtime reduction mediated 
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by TF-MVs when compared to NPP alone. This technique is more sensitive 
without reagent but the variability increased. 
In vivo the correlation between TF-MV and thrombosis may become more or 
less strong depending on the type of tumour/cancer present in a patient 
(Kasthuri, Taubman et al. 2009, Zwicker, Liebman et al. 2009, Zwicker 
2010).  Therefore, additional in vivo studies examining the relationship 
between tumour/cancer progression, thrombosis and TF-MV is critical.  
In addition, atomic force microscopy, a high-sensitive technique able to 
image biological samples in aqueous fluids was recently proposed for the 
detection and quantification of CD41-positive MVs (Yuana, Oosterkamp et 
al. 2010). This technique should be developed and validated for TF-MVs and 
compared with FCM, TEM and TGA. 
 
3.6 Conclusions 
 
This is the first study that uses FCM, TEM and TGA to characterize MVs. 
MDA-MB-231 releases MVs whose size was 121 +/-54 nm by TEM. TGA is 
a useful technique to study the PCA of tumour cell-derived MVs whatever 
their size. It should be combined by high-sensitive sizing and counting 
techniques such as AFM in order to estimate the concentration of specific 
MVs (i.e. TF-MVs).  TGA should be validated and used to study TF-MV in 
plasma from healthy subjects and patients. 
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4 Adapted thrombin generation assay to study procoagulant 
activity of plasmatic extracellular vesicles 
 
Original article in Blood Coagulation and Fibrinolysis 2013: 
Inhibition of tissue factor pathway inhibitor increases the sensitivity of 
thrombin generation assay to procoagulant microvesicles. 
 
Damien Gheldof, François Mullier*, Bernard Chatelain, Jean-Michel 
Dogné*, Christian Chatelain*. 
 
Thrombin generation assay is a useful technique to study procoagulant EVs. 
This technique coupled with filtration and inhibitors provide important EVs 
PCA information. However, this technique suffers from a lack of sensitivity 
for detection of EVs-TF activity due to the presence of TFPI. For the in vitro 
study this limitation can be easily overcome by a large production of EVs-TF 
(increased the number of cells). However, it’s possible that EVs-TF levels 
circulating in cancer plasma patient were very low. So, we need a highly 
sensitive technique to study the EVs PCA in plasma from leukemic patient.  
In these study, two methods are used to increase the TGA sensitivity: TFPI 
inhibition and plasma dilution.  
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4.1 Abstract 
 
INTRODUCTION: Patients with cancer have a 7- to 10-fold increased risk 
of developing venous thromboembolism (VTE). Circulating microvesicles 
(MVs) could be a predictive biomarker for VTE in cancer. Thrombin 
generation assay (TGA) is a useful technique to detect procoagulant activity 
of MVs. However, TGA suffers from a lack of sensitivity due to the presence 
of Tissue Factor Pathway Inhibitor (TFPI) in plasma. 
AIMS: To improve the sensitivity of TGA to tissue factor (TF) by limiting 
the interference of TFPI. 
METHODS: Serial dilutions of MDA-MB231 cells were incubated for 45min 
at 37°C to generate MVs. Samples were then centrifuged and supernatants 
which contain MVs were used for TGA. Normal pooled plasma was 
incubated with inhibitor of TFPI or was diluted twice to decrease plasma level 
of TFPI. Lagtime was used as a surrogate marker of TGA to detect 
procoagulant activity of MVs. 
RESULTS: i) Inhibition of TFPI decreased twice the cell concentration 
needed for a significant reduction of lagtime and decreased 2.4-fold the intra-
assay variability. ii) Plasma dilution had no impact on the TGA sensitivity 
when TGA was triggered by MVs derived from MDA-MB-231. 
CONCLUSIONS: Thrombin generation is a very sensitive method to study 
the procoagulant activity of TF-MVs. The sensitivity can be increased by 
inhibition of TFPI with specific monoclonal antibody against its Kunitz 
Domain I. A two times plasma dilution is an interesting cheaper alternative 
to study the procoagulant activity of MV by TGA with a good sensitivity, 
especially when low plasma quantities are available.  
Abbreviations : microvesicles (MVs)- tissue factor (TF)- procoagulant 
phospholipids (PL)- tissue factor bearing microvesicles (TF-MVs)- venous 
thromboembolism (VTE)- thrombin generation assay (TGA)- tissue factor 
pathway inhibitor (TFPI)-normal pooled plasma (NPP)- endogen thrombin 
potential (ETP)- standard deviation (SD)- procoagulant activity (PCA) 
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4.2 Introduction 
 
Association between cancer and thrombotic disorders is well described 
(Debaugnies, Azerad et al. , Davila, Amirkhosravi et al. 2008). 
Hypercoagulability in cancer is a multifactorial process that involves both 
physical and biochemical procoagulant mechanisms. Several substances 
overexpressed by malignant cells including cytokines, cancer procoagulant (a 
cysteine protease) and tissue factor bearing microvesicles (TF-MVs), are 
known to activate the coagulation cascade. MVs are considered as a key 
component of the haemostatic system. They are small membrane vesicles 
shed from normal and/or tumour cells following activation or apoptosis. They 
can be captured in the developing thrombus and can lead to thrombin 
generation by expression of procoagulant phospholipids (PL) and TF 
(Mackman 2004, Furie and Furie 2008). Moreover, several studies strongly 
suggest that TF-MVs and TF-MV activity may have prognostic value in 
identifying cancer patients with increased risk of developing venous 
thromboembolism (VTE) (Zwicker 2008, Wang, Geddings et al. 2012). 
Several techniques are currently used to study the procoagulant activity of 
TF-MVs (Key and Mackman). Two distinct types of assays for measurement 
of TF-MV activity in human plasma are reported using either antibody-
mediated MP capture or isolation by centrifugation (Key and Mackman). 
However, preanalytical steps associated with these methods (centrifugation 
and/or washing)  could impact MV size, number and activity (Yuana, Bertina 
et al.). When MVs could be isolated and concentrated from the patient 
plasma, TGA should be a great technique to observe the procoagulant 
activity. Thrombin generation assay (TGA) appears as a promising method to 
assess the impact of TF-MVs on coagulation (Dargaud, Luddington et al. 
2007). Although TF activity assay like TGA is more sensitive than ELISA 
(Key and Mackman), TGA also suffers from a lack of sensitivity which is 
notably due to the presence of tissue factor pathway inhibitor (TFPI) in 
plasma (Yamamuro, Wada et al. 1998). TFPI is an endogenous anticoagulant 
protein of the serine protease inhibitor family. TFPI consists of three Kunitz 
type domains ; the first domain is responsible for FVIIa/TF inhibition and the 
second Kunitz domain is a FXa inhibitor (Shimura, Wada et al. 1996). Human 
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plasma level of  total TFPI is 68.7 +/-14.1ng/ml and for the free TFPI 17.7 
+/- 5.4ng/ml and 51.1 +/-12.0ng/ml are lipoprotein associated (Yamamuro, 
Wada et al. 1998). 
 The aims of this study were to compare the impact of the use of a TFPI 
inhibitor with the use of diluted plasma on the sensitivity of TGA to assess 
the procoagulant activity of MVs. First, we studied the impact of TFPI 
inhibitor or plasma dilution on thrombin generation induced by known 
concentrations of TF and PL (dilution of PPP low reagent). We then studied 
the impact of TFPI inhibitor or plasma dilution on thrombin generation 
sensitivity induced by MDA-MB-231 derived MVs. 
 
4.3 Material and methods 
 
4.3.1 Preparation of normal-pooled plasma  
Normal pooled-plasma was prepared as previously described (Robert, 
Ghiotto et al. 2009). Platelet-free plasma was obtained from a first 
centrifugation at 2,500g for 15min at room temperature (RT) (Heraeus 
Multifuge 1S-R, Sysmex Benelux, Etten-Leur, The Netherlands) with a light 
brake only, within one hour after sampling. The platelet-poor plasma was 
collected and transferred into a polypropylene hemolysis tube with a 
micropipette. Aspiration was stopped 1cm above the buffy-coat while 
avoiding the buffy-coat. Platelet-poor plasma was centrifuged a second time 
at 2,500g for 15min at RT. The platelet-free plasma was collected into a fresh 
tube using a micropipette, while leaving about 100μl of platelet-free plasma 
at the bottom of the tube and pooled. The normal pooled plasma (NPP) was 
frozen in liquid nitrogen and stored at -80°C. 
4.3.2 Cell culture 
Adherent MDA-MB-231 breast cancer cells (ATCC number HTB-26) were 
obtained from the American Type Culture Collection (Manassas, VA, USA) 
and were cultured in RPMI-1640 medium (Lonza, Verviers, Belgium) 
supplemented with 10% fetal bovine serum (Lonza, Verviers, Belgium). Cells 
were maintained in a 5% CO2 humidified atmosphere at 37°C. Natrium 
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bicarbonate was set at 1.5g/L to control the pH. Cell viability was controlled 
by the trypan blue exclusion test. 
4.3.3 In vitro generation of MVs 
A modified version of the protocol reported by Davila et al. was performed 
(Davila, Amirkhosravi et al. 2008). Cells were adjusted to the desired 
concentrations in PBS and then incubated for 45min at 37°C without any 
stirring. Samples were centrifuged at 4,500g for 15 min and the cell 
supernatants which contain MVs were used in TGA. 
4.3.4 Thrombin generation assay  
To study the TGA sensitivity, a modified version of the method developed by 
Hemker was used. The first experiments were performed with PPP low 
reagent which corresponds to 1pM TF and 4µM PL (Thrombinoscope BV). 
This activator of clotting was diluted 10-fold or 100-fold in some experiments 
in order to study the sensitivity of TGA with low TF concentration and low 
concentration of PL. In a second step of the study, cell suspensions or in vitro 
generated MV fractions from 500 to 20,000 cells/ml were used as the source 
of TF and phospholipids (PL). Eighty µl of NPP and 20µl of different TF and 
PL concentrations or MV fractions were mixed in a 96-well microtiter plate 
(Thermo Immulon 2HB, USA) and were incubated for 10min at 37◦C. PBS 
alone was tested as a negative control. The next steps of the protocol were 
already described (Robert, Ghiotto et al. 2009). Briefly, the plasma clotting 
was triggered by the addition of 20μl fluorogenic substrate/calcium chloride 
buffered solution at 37◦C. A calibration curve was also performed for each 
blood draw using 80μl of NPP and 20μl of thrombin calibrator and 20μl of 
substrate/calcium chloride-buffered solution. The reaction of substrate 
hydrolysis was monitored on a microplate fluorometer Fluoroskan Ascent FL 
(Thermo Labsystems) with a 390/460-nm filter set (excitation/emission) 
using the Thrombinoscope® software version 3.0 (Synapse BV).  The 
thrombin generation curves and more relevant parameters: lagtime which 
correspond to the initiation of clot formation (min), endogenous thrombin 
potential (ETP, nM/min) and thrombin peak (nM)) were calculated using 
software Thrombinoscope®. The results were expressed as means ± standard 
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deviation (S.D.) in percent in comparison of control (CTL) which represent 
100%. 
4.3.5 Inhibition of TPFI  
Plasma TFPI was inhibited with a monoclonal antibody (ADG4903 American 
Diagnostica Gmbh) against Kunitz Domain I of human TFPI. Before TGA 
analysis, NPP was incubated 15min at 37°C with antibody at 10µg/ml in final 
concentration, before performing the experiment. PPP low reagent undiluted 
(1pM TF and 4μM PL) or diluted 10 times (0.1pM TF and 0.4μM PL) was 
used. Cell suspensions or in vitro generated MV fractions from 500 to 20,000 
cells/ml were used as the source of TF and PL. 
4.3.6 Plasma dilution 
NPP was diluted twice to decrease level of TFPI. PPP low reagent undiluted 
or diluted 10 times was used. In vitro generated MV fractions from 500 to 
20,000cells/ml were used as a second source of TF and PL. 
4.3.7 Statistics 
Comparison between different conditions was performed using Wilcoxon test 
on GraphPad Prism® software (version 5.01). Significant results have a P-
value<0.05. 
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Figure 12: Thrombin generation experiments. Curve data are presented as mean with n=3. 
All the results are representative of the 3 independent experiments.  A) Impact of antibody 
anti-TFPI on thrombin generation curve induced by 1pM TF and 4µM PL. CTL was NPP 
spiked with 1pM TF and 4µM PL without antibody. B) Impact of TFPI inhibitor on thrombin 
generation induced by 0.1pM TF and 0.4pM PL. CTL was NPP spiked with 0.1pM TF and 
0.4µM PL without antibody (n=3). 
 
4.4 Results 
 
4.4.1 Effects of TFPI inhibition on TGA sensitivity triggered by 1pM TF 
and 4µM PL or 0.1pM TF and 0.4µM PL 
Inhibition of TFPI by antibody increased the response of thrombin generation 
to TF and PL (Figure 12). A significant increase in peak and ETP and a 
significant decrease in lagtime were observed when NPP was incubated with 
anti-TFPI. The difference in lagtime and ETP was more important with 
0.1pM TF and 0.4µM PL in comparison to 1pM and 4µM PL. A significant 
difference was only observed on the peak parameter with 1pM TF and 4µM 
PL (Figure 13). 
4.4.2 Effect of plasma dilution on TGA sensitivity triggered by 0.01pM TF 
and 0.04µM PL 
Dilution of plasma significantly increased the difference between thrombin 
generation initiated by 0.01pM TF and 0.04µM PL and thrombin generation 
without TF and PL (Figure 14 A and B). For the lagtime mean the difference 
between CTL and 0.01pM TF and 0.04µM PL was 16% and insignificant 
when NPP was not diluted and 38% when NPP was diluted two times. For 
the peak mean the difference between CTL and very low TF and PL was 27% 
and insignificant when NPP was not diluted and 59% when NPP was diluted 
A Thrombin Generation (1pM TF and 4µM PL).
0 10 20 30
0
100
200
300
400
anti-TFPI
CTL
Time (min)
T
h
ro
m
b
in
 (
n
M
)
B Thrombin Generation (0.1pM TF and 0.4µM PL)
0 10 20 30 40 50
0
50
100
150
anti-TFPI
CTL
Time (min)
T
h
ro
m
b
in
 (
n
M
)
66 
 
two times. For the ETP mean the difference between CTL and 0.01pM TF 
and 0.04µM PL was 31% NPP and insignificant and 88% when NPP was 
diluted two times (Figure 15). 
 
 
 
 
Figure 13. Thrombin generation parameters (Lagitme, Peak, ETP) expressed in percentages 
+/-SD. Graphs show the difference between thrombin generation curves when NPP is 
incubated or not with antibody anti-TFPI. Thrombin generation is triggered with 1pM TF and 
4µM PL and with 0.1pM TF and 0.4µM PL. CTL use is NPP without antibody against–TFPI 
spiked with 1pM TF and 4µM PL or 0.1pM TF and 0.4µM PL. Significant differences 
(P<0.05) were indicated with an asterisk *. 
 
 
 
 
 
Figure 14. Thrombin generation experiments. Curve data are presented as means with n=9. 
All the results are representative of the 9 independent experiments.  A. Thrombin generation 
curves with undiluted NPP. Thrombin generation is triggered by 0.01pM TF and 0.04µM PL. 
CTL use in is NPP undiluted spiked with PBS (no TF and PL) B. Thrombin generation curves 
with NPP diluted two times. Thrombin generation is triggered by 0.01pM TF and 0.04µM 
PL. CTL use in is NPP diluted two times spiked with PBS (no TF and PL). 
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4.4.3 Effect of TFPI inhibition and plasma dilution on TGA sensitivity 
triggered by MVs derived from different concentrations of MDA-
MB-231 cells 
Lagtime was the most sensitive TGA parameter when the reaction was 
activated by MVs derived from MDA-MB-231. The use of TFPI inhibitor 
decreased two times the cell concentration needed to produce enough MVs 
for a significant reduction of lagtime. Without TFPI inhibitor, the cell 
concentration required to produce MVs to significantly reduce lagtime was 
5,000cells/ml. With TFPI inhibitor, only 2,500cells/ml were required to 
produce MVs to significantly reduce lagtime (Figure 16A and B). Moreover, 
the use of TFPI inhibitor decreased 2.4-fold the intra-assay variability.  
Plasma dilution had no impact on the TGA sensitivity when TGA was 
triggered by MVs derived from MDA-MB-231 (Figures 17A and B). CTL 
use in is NPP diluted two times spiked with PBS (no TF and PL). 
 
 
 
 
 
 
Figure 15. Thrombin generation curves parameters (Lagitme, Peak, ETP) data are presented 
as means +/-SD with n=9. All the results are representative of the 3 independent experiments. 
Graphs show the difference between thrombin generation curves when NPP is diluted or not. 
Thrombin generation is triggered with 0.01pM TF and 0.04µM PL. A lagtime parameter in 
% +/- SD. B peak parameter in %+/- SD. C ETP in % +/- SD. CTL use is NPP diluted or not 
unspiked with 0.01pM TF and 0.04µM PL. Significant differences (P<0.05) were indicated 
with an asterisk *. 
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Figure 16.A. Thrombin generation curve parameter lagtime. Data are presented as means +/-
SD with n=3. All the results are representative of the 3 independent experiments. A. Lagtime 
of NPP without antibody against-TFPI activated by MVs derived from MDA-MB-231 
contained in supernatant of different cell concentrations. CTL use is NPP without antibody 
against TFPI spiked PBS. B. Lagtime of NPP activated by MVs derived from MDA-MB-231 
and incubated with antibody against-TFPI. CTL use is NPP incubated with antibody against 
TFPI spiked PBS. Significant differences (P<0.05) were indicated with an asterisk *. 
 
 
 
 
 
 
 
 
Figure 17.A. Thrombin generation curve of undiluted NPP activated by MVs derived from 
MDA-MB-231 at different cell concentrations. CTL use is NPP without antibody against 
TFPI spiked PBS. B. Thrombin generation curve parameter (lagtime) with NPP diluted two 
times and activated by MVs derived from MDA-MB-231 at different cell concentrations. 
CTL use is diluted NPP. Significant differences (P<0.05) were indicated with an asterisk * 
(vs CTL). 
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4.5 Discussion 
 
 VTE prophylaxis during systemic chemotherapy is not recommended 
for ambulatory patients with cancer (Khorana, Streiff et al. 2009). One of the 
reasons is the absence of validated biomarkers that allow the identification of 
a group of outpatients that would benefit for thromboprophylaxis (Khorana, 
Kuderer et al. 2008) The circulation of active TF associated with MVs has 
been considered as a promising biomarker to predict the risk of VTE in cancer 
patients (Manly, Wang et al. 2010, Zwicker 2010, Owens and Mackman 
2011). An ongoing phase III study (MicroTEC, NCT00908960) in advanced 
cancer patients with high levels of TF-MVs has been designed to evaluate the 
benefit of primary thromboprophylaxis in reducing thromboembolic 
complications and to validate the prognostic usefulness of measuring TF-
MVs (Menapace and Khorana , Zwicker, Liebman et al. 2009). However, 
validation and standardization of techniques measuring TF-MVs is required 
before considering cut-off values of this biomarker in risk-stratification 
approaches. In a previous study, we compared flow cytometry, electron 
microscopy and TGA to determine the size, the concentration and the PCA of 
tumour MVs. In this study, we focused on the optimal use of TGA to quantify 
the activity of TF-MVs. The aim was to compare the impact of plasma 
dilution and TFPI inhibition to increase the sensitivity of TGA. In the first 
part of the study, thrombin generation was triggered by known concentration 
of TF and PL. The inhibition of TFPI by blocking antibody increases the 
thrombin generation. The peak and the ETP are increased and lagtime is 
decreased when TFPI is inhibited. These results are in accordance with 
previous study (Gorczyca, Nair et al.). Moreover, the effect of TFPI inhibition 
on thrombin generation curves is more striking when system is triggered by 
0.1pM TF and 0.4µM PL (Figures 16 and 17). These results suggest that 
thrombin generation is more sensitive when a diluted activator is used 
(Duchemin, Pan-Petesch et al. 2008). Strong activator of thrombin generation 
could hide some procoagulant effect. These first results led us to use weak 
activator of thrombin generation. The effect of plasma dilution on sensitivity 
was therefore measured with 0.01pM of TF and 0.04µM PL as activator. 
These results show that the signal of thrombin generation triggered by 
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0.01pM TF and 0.04µM PL in comparison of CTL (no TF and PL) is higher 
when plasma is diluted two times. Plasma dilution increases two times in 
average the response of thrombin generation assay to 0.01pM TF and 0.04µM 
PL. These results are in accordance with a previous study which showed that 
coagulation inhibition factors are most affected by plasma dilution 
(Duchemin, Pan-Petesch et al. 2008). 
In order to assess the impact of TFPI inhibitor or plasma dilution on thrombin 
generation sensitivity for MV PCA detection, different MDA-MB-231 cell 
concentrations and cells derived MVs concentrations were used as 
coagulation activator. Lagtime parameter appears as the most sensitive 
parameter for TF-MV procoagulant activity (PCA) detection (Duchemin, 
Pan-Petesch et al. 2008). Thus, our results show that only MVs from 5,000 
cancer cells/ml are required to significantly decrease the lagtime of thrombin 
generation curves. Other parameters such as ETP and Peak are only 
influenced by higher concentrations of MVs (MVs generated by > 10,000 
cancer cells/ml). Moreover, our results show that lagtime can be significantly 
reduced by MVs derived from 2,500cells when TFPI is inhibited and that 
TFPI inhibition decreases the thrombin generation variability. The same 
conclusions can be drawn with the other TGA parameters (ETP, peak). Two 
times plasma dilution did not impact on the thrombin generation sensitivity 
to MVs. However, additional plasma dilution (> two times) do not give 
interpretable curves whatever the parameters used (lagtime, ETP, peak). This 
finding is of peculiar interest for TGA experiments when low plasma 
quantities are available (e.g. plasma from small animal experiments). 
In conclusion, thrombin generation is a very sensitive method to study the 
procoagulant activity of TF-MVs. The sensitivity can be increased by TFPI 
inhibition. We recommend the TFPI inhibition with specific monoclonal 
antibody against Kunitz Domain I of human TFPI at 10µg/ml in final 
concentration for TGA experiments. It allows an augmented sensitivity of 
TGA and lower intra-assay variability. A two-fold plasma dilution is a 
valuable and cheaper alternative to study the procoagulant activity of MV by 
TGA with a good sensitivity, especially when low plasma volumes are 
available.  
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5 Leukemic cells line can produce procoagulant 
extracellular vesicles in vitro 
 
Original article Thrombosis Research 2014: 
Microparticle bearing tissue factor: a link between promyelocytic cells 
and hypercoagulable state. 
 
Gheldof Damien, Mullier François, Bailly Nicolas, Devalet Bérangère, 
Dogné Jean-Michel, Chatelain Bernard, Chatelain Christian 
In this study, we try to confirm that leukemic cells can shed procoagulant EVs 
and that these EVs have a major role in thrombotic activity of leukemic blasts. 
To assess this hypothesis, we use the combination of TGA, TEM and CMF 
to study in vitro EVs derived from acute leukaemia M3 subtype cell lines 
(HL-60 and NB4). The second part of this research is the study of 
anthracyclines impact on these cells and derived EVs PCA.  
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5.1 Abstract 
 
Patients with haematological malignancies have a 28-fold increased risk of 
venous thromboembolism (VTE). Among patients with acute myelogenous 
leukaemia (AML), the 2-year cumulative incidence of VTE is 5.2%. Several 
studies suggest that microvesicles (MVs) harboring TF may play a role in 
VTE and disseminated intravascular coagulation (DIC) in acute 
promyelocytic leukaemia (APL). 
The aim of this study was to assess the capacity of untreated APL cells to 
shed procoagulant MVs.APL cells (NB4 and HL-60 cell lines) and MVs were 
separated by filtration (0.1-0.22-0.45-0.65µm). The procoagulant activity 
(PCA) was assessed by thrombin generation assay (TGA). Alternatively, 
MVs were incubated with anti-Tissue Factor (TF) antibodies, with annexin V 
to assess the contribution of TF and phospholipids (PL) to the PCA, 
respectively. 
NB4 cells had a high PCA mainly triggered by MVs of size under 0.45 µm. 
The PCA of MVs was related to the expression of active TF and PL. HL-60 
cells had a weaker PCA since TF is mostly present in its inactive form. 
Moreover, HL-60 do not produce MVs<0.65 µm associated with PCA.  
MVs could have a predicting value for VTE and DIC in patients with acute 
promyelocytic leukaemia and could inform physicians about the optimal use 
of a thromboprophylaxis. 
Abbreviations: venous thromboembolism (VTE); acute myelogenous 
leukaemia (AML); microvesicles (MVs); disseminated intravascular 
coagulation (DIC); acute promyelocytic leukaemia (APL); procoagulant 
activity (PCA); Tissue Factor (TF); phospholipids (PL); acute lymphoblastic 
leukaemia (ALL); daunorubicin (DNR); normal pooled plasma (NPP); 
Transmission electronic microscopy (TEM); flow cytometry (FCM); 
thrombin generation assay (TGA); fluorescein isothiocyanate (FITC); 
phycoerythrin (PE); all-trans retinoic acid (ATRA) 
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5.2 Introduction 
 
Despite the remarkable improvement of survival in patients with acute 
promyelocytic leukaemia for the past twenty years, a significant early 
mortality remains due to bleeding and thrombotic complications (Kwaan and 
Rego 2010). In patients with acute leukaemia, substantial activation of 
coagulation and resulting factor consumption result in localized thrombosis, 
widespread bleeding or both, hence termed the thrombohaemorrhagic 
syndrome (Ku, White et al. 2009). Thrombosis is a common complication of 
patients with malignancies (Falanga, Barbui et al. 2008). Patients with 
haematological malignancies have a 28 fold increased risk to develop venous 
thromboembolism (VTE) (Tesselaar, Romijn et al. 2007, Davila, 
Amirkhosravi et al. 2008). Among patients with acute myelogenous 
leukaemia (AML), the incidence of VTE is 5.2%, and among patients with 
acute lymphoblastic leukaemia (ALL), the incidence of VTE is 4.5% in the 
first two years of disease (Ku, White et al. 2009). 
Treatment of patients with AML requires cytotoxic chemotherapy.  Cytosine 
arabinoside and anthracyclines such as daunorubicin (DNR) are the most 
commonly used worldwide and are recommended as the standard of care 
(Fernandez 2010). Patients with AML often present with clinical or 
laboratory features demonstrating an activation of coagulation, such as 
prothrombin fragments 1 and 2, thrombin-antithrombin complexes, D-
dimers, and ﬁbrinopeptides A and B (Barbui and Falanga 2001). Ten % of 
APL patients die as a consequence of bleeding diathesis. These patients have 
increased procoagulant activity that generates the clinical syndromes often 
encountered, such as VTE and DIC (Ma, Liu et al. 2012).  
Despite their influence on mortality and morbidity, the mechanisms inducing 
a hypercoagulable state are not fully understood to date. Multifactorial causes 
include physic immobility, chemotherapy adverse effects (Pollyea, Kohrt et 
al. , Schneider, Van Dreden et al.) and the overexpression of several 
procoagulant substances by cancer cells (cytokines, cysteine protease and 
tissue factor) (Davila, Amirkhosravi et al. 2008). Recent studies strongly 
demonstrate that cancer cells shed microvesicles (MVs) harbouring tissue 
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factor (TF-MVs). These TF-MVs have a primary role in thromboembolism 
by expression of procoagulant phospholipids (PL) such as 
phosphatidylserine, and TF. Tissue factor, the most potent initiator of the 
coagulation cascade, plays a critical role in haemostasis (Davila, 
Amirkhosravi et al. 2008, Petropoulou, Gerotziafas et al. 2008). TF is a 
transmembrane receptor which binds the coagulation serine protease 
FVII/VIIa to form a biomolecular complex that functions as the primary 
enhancer of coagulation in vivo. This complex activates both FX and FIX and 
leads to the generation of thrombin and fibrin (Kasthuri, Taubman et al. 2009, 
Wang, Manly et al. 2009). TF is present in blood in various forms. However, 
when carried by MVs, TF exerts its most intense procoagulant activity 
(Davila, Amirkhosravi et al. 2008, Mackman 2009, Mackman and Taubman 
2009, Gheldof, Hardij et al. 2013). Microvesicles are considered as key 
components of the haemostatic system. They are small membrane vesicles 
shed from normal and/or tumour cells following activation or apoptosis. They 
can be captured in the developing thrombus and can lead to thrombin 
generation by expression of PL and TF (Mackman 2004, Furie and Furie 
2008). Moreover, several studies strongly suggest that TF-MVs and their 
activity may have prognostic value in identifying cancer patients with 
increased risk of developing venous thromboembolism (VTE) (Owens and 
Mackman , Wang, Geddings et al. , Zwicker 2008, Zwicker, Liebman et al. 
2012). 
Understanding the pathogenic mechanisms of APL-related thrombosis is an 
important step towards developing preventive strategies against thrombotic 
complications of APL. The aim of this study was to assess the role of 
microvesicles derived from acute promyelocytic leukaemia cells, and to 
assess the contribution of TF and phosphatidylserine contained in MVs to 
activate the coagulation cascade. The effect of chemotherapeutic agents on 
MV procoagulant activity was also studied.  
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5.3 Methods 
 
5.3.1 Design of the study 
In order to confirm the role of MVs inleukemic cell lines, we assessed the 
cellular ability to produce MVs at the membrane surface by electron 
microscopy. In a second time, the expression of TF and PL on MV surface 
was studied by flow cytometry. Finally, MV PCA of two APL cell lines and 
the impact of chemotherapeutic on cells and MVs were studied by thrombin 
generation assay which provides information on their capacity to generate 
activated thrombin. 
5.3.2 Cell culture 
Acute myeloid leukemic cell lines (NB4 and HL-60) were cultured for 48h as 
previously shown (Gheldof, Hardij et al. 2013) in RPMI-1640 medium 
(Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum 
(Lonza, Verviers, Belgium). Cells were maintained in a 5% CO2 humidified 
atmosphere at 37°C. Natrium bicarbonate was set at 1.5g/L to control the pH. 
Cell viability was controlled by the trypan blue exclusion test. 
5.3.3 Preparation of normal-pooled plasma and platelet-free plasma 
Normal pooled-plasma was prepared as previously described (Robert, 
Ghiotto et al. 2009, Mullier, Bailly et al. 2013) Blood was taken from forty-
two healthy individuals by venipuncture in the antecubital vein and collected 
into 0.109M sodium citrate (9:1 v/v) tubes (Venosafe®, Terumo, Belgium) 
using a 21-gauge needle (Terumo, Belgium). The platelet-poor plasma (PPP) 
was obtained from the supernatant fraction of the blood tubes after a double 
centrifugation for 15min at 1500g at room temperature. Immediately after 
centrifugation, PPP from the 42 donors were brought together to obtain the 
normal pooled plasma (NPP) which was frozen at – 80°C without any delay. 
Frozen NPP samples are thawed and heat to 37°C for 5min just before 
experiment.   
.  
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5.3.4 Preparation of samples for Transmission electronic microscopy 
(TEM) observation 
Samples were prepared as previously demonstrated (Gheldof, Hardij et al. 
2013). Briefly, cells and MVs were pelleted by ultracentrifugation. The pellet 
was fixed for TEM observation by glutaraldehyde and osmium tetraoxide. 
Samples were further washed and dehydrated by successive baths in ethanol 
and impregnation of samples in resin was then performed. After resin 
polymerization, samples were cut with an ultra-microtome and stained with 
uranyl acetate and lead citrate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Transmission electron microscopy of cells and derived MVs after 
ultracentrifugation at 100,000g during 90min. a) Scale bar = 1 µm; b),c),d),e) Scale bar =200 
nm.;  f Scale bar=100nm. 
f) e) 
a) b) 
c) 
d) 
e) f) 
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5.3.5 Expression of TF and phosphatidylserine by flow cytometry (FCM) 
Expressions of TF and phosphatidylserine on NB4 cells and MVs were 
carried out by FCM a BDIS FACS AriaI® flow cytometer (BD Biosciences, 
San Jose, CA, USA) with 488nm Coherent® SapphireTM solid state as light 
source was used for FCM measurements. Diva-6 software (Becton-
Dickinson) was used for all data acquisition. MV fraction derived from cells 
cultured during 48h were labelled with CD142-PE and Annexin V-FITC. The 
size of MVs was defined using a blend of monodisperse fluorescent beads 
(Megamix, BioCytex, Marseille, France) of three diameters (0.5, 0.9 and 3 
µm), a protocol already described (Gheldof, Hardij et al. 2013). 
5.3.6 Measurement of the MV procoagulant activity (PCA) by thrombin 
generation assay (TGA) 
PCA was measured by TGA according to a modified version of the method 
developed by Hemker (Hemker, Giesen et al. 2002) . In a 96-well round 
bottom plate, 20 µL of prewarmed trigger solution is added to one well and 
20 µL of prewarmed calibrator, i.e. 600 nM alpha2M-thrombin complex to 
another; 80 µL of plasma is added to both wells. Ca++ is added together with 
the substrate at zero time (Fluka Solution). Readings are done in a microtiter 
plate fluorometer (Fluoroscan Ascent, Thermolabsystems, Helsinki, Finland), 
at 37°C, provided with a dispenser that is filled with FluCa solution. When 
the experiment is started, the dispenser squirts 20 µL of FluCa solution in 
each well at zero time. Cell suspensions or MV<0.65μm fractions from cells 
cultured two days were used as the source of TF and PL. 80 µl of NPP and 
20µl of cell suspensions or MV fractions were mixed Culture medium was 
tested as a negative control. This protocol was described previously by Robert 
and coll. (Robert, Ghiotto et al. 2009). All the experiments were performed 
in triplicate. 
5.3.7 Effect of MV size on PCA 
Cells and MV fractions were filtered through 0.1, 0.22, 0.45 or 0.65µm 
membranes (Ultrafree-MC; Amicon, Bedford, MA, USA). Cells and filtrates 
were compared by TGA (1 experiment in triplicate). 
5.3.8 Contribution of TF and PL to MVs PCA 
For estimation of TF contribution to PCA, MVs < 0.65µm originating from a 
2-day culture of cells were pre-incubated 10 min at 37°C with monoclonal 
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antibodies HTF-1 (BD Biosciences, Erembodegem, Belgium), a TF-activity 
neutralizing antibody (Wang, Manly et al. 2009) and  the PLs-mediated 
activity was blocked with Annexin V before TGA was performed  as 
previously described (Gheldof, Hardij et al. 2013). Three independent 
experiments were performed in triplicate. 
5.3.9 Effect of daunorubicin (DNR) on MV and cell PCA 
Acute myeloid leukemic cells lines were cultured 48h with 0.2 μg/ml of DNR 
(Sanofi-aventis, Belgium) and tested in TGA. 
5.3.10 Effect of tissue factor activator on cells PCA 
Acute myeloid leukemic cells lines and MVs derived were incubated for 2 
minutes with 500 nM HgCl2   (a potent TF activator)(Chen and Hogg 2013) 
in PBS before testing with TGA. 
5.3.11 Statistics 
Comparison between different conditions was performed using Wilcoxon test 
a nonparametric test that compares two paired groups on GraphPad Prism® 
software (version 5.01). 
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5.4 Results 
 
5.4.1 Evidence for MV shedding and determination of MVs size by TEM 
Figure 18 shows image of NB4 cells studied by TEM. It clearly illustrates 
the spontaneous release of MVs from these tumour cells. The bilayer 
membrane of the MVs is observed. The MV mean size after centrifugation 
was 337nm [range: 90 nm to 832 nm]. 52% of MVs are comprised between 
200 nm and 400 nm. 
5.4.2 Characterization of NB4 cells and NB4 derived MVs by flow 
cytometry 
Figure 19 shows that MVs derived from NB4 cells are positive for tissue 
factor and positive for anV. A small proportion of MVs are positive for both 
TF and AnV.  
. 
 
 
 
 
 
 
 
Figure 19. Expression of TF (CD142) and AnV (CD-227) on MVs<0.65μm after cell 
depletion. A) Analysis of tumour microvesicles. Dual fluorescence analysis of NB4 cells 
stained with AnV fluorescein isothiocyanate (FITC) (FL1) and CD142–phycoerythrin (PE) 
(FL2). CD142+ AnV+ MVs are represented as yellow dots, CD142+ AnV- MVs as red dots, 
AnV+ CD142- MVs as blue dots and background noise or other MVs as orange dots.  B) 
Backgating of CD142+ AnV+ MVs (yellow dots), CD142+ AnV- MVs (red dots) and AnV+ 
CD142- MVs (blue dots) on FSClog-SSC log cytogram. 
 
A) B) 
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5.4.3 PCA Characterization of two acute promyelocytic leukaemia cells 
lines (NB4 and HL-60) by thrombin generation 
NB4 cells and HL-60 cells can stimulate thrombin generation. HL60 cells 
reduce the lagtime 3.9-fold and increase the peak 1.6-fold when compared 
with control (Figure 20.B) and NB4 cells decrease the lagtime 12.6-fold and 
increase the peak 7.1-fold in comparison to control. No PCA is observed in 
HL-60 filtered with 0.65 µm membrane (no statistical difference in lagtime 
peak and endogenous thrombin potential (ETP)) (Figure 20.B). By contrast, 
NB4 cells can support thrombin generation activity when filtered at different 
sizes. MVs of sizes <0.65 and <0.45 µm decrease the lagtime 6.2- and 2.9-
fold, respectively and increase the peak of thrombin 4.4- and 2.3-fold, 
respectively. MVs of sizes lower than 0.22 µm reduce the lagtime 1.9-, and 
increase the peak 1.5 (Figure 20.A). No procoagulant activity is associated 
with medium filtered through 0.1 µm. Thrombin generation activity of MVs 
derived from NB4 cells <0.65µm is abolished when anti-TF antibodies or 
AnV is added during preincubation (Figure 20.C). 
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Figure 20. Thrombin generation curves and histograms of lagtime and peak parameters 
(n=6). A) In control condition (CTL), normal pooled plasma (NPP) was spiked with culture 
medium. NPP spiked with NB4 cells (NB4), and NB4 cells filtered through membranes with 
various sizes 0.1µm/0.22µm/0.45µm/0.65µm (MVs<…). B) Thrombin generation 
experiments. In control condition (CTL), NPP was spiked with culture medium. NPP spiked 
with HL-60 cells (HL-60), and HL-60 cells filtered through membranes with various sizes 
0.45µm/0.65µm (MVs<…). C) Thrombin generation experiments. NPP was spiked with 
MVs derived from NB4 filtered at 0.65µm incubated with HTF-1 (MVs<0.65µm+ HTF-1) 
and with AnV (MVs<0.65µm+AnV). In control NPP spiked with culture medium and HTF-
1. Data with significant difference in comparison to control are indicated with * (p<0.05). 
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5.4.4 PCA characterization of two acute promyelocytic leukaemia cells 
lines (NB4 and HL-60) treated with daunorubicin by thrombin 
generation 
Addition of daunorubicin to cultures increases the thrombin generation by 
NB4 and HL-60 cells and derived MVs of <0.65μm. Lagtime of NB4 cells is 
slightly decreased by this treatment. No significant lagtime difference 
between MVs<0.65μm and MVs<0.65μm DNR is observed. The most 
affected parameter by DNR treatment is the peak of thrombin generation. 
Treated cells have a 1.4 fold peak increase and MVs derived from these cells 
have a 1.3-fold peak increase when compared with untreated cells. The same 
effect is observed on MVs<0.45 – 0.22μm since the peak is significantly 
increased by DNR (Figure 21). Lagtime of HL-60 is decreased 1.2-fold when 
cells are treated, and peak is increased by a 1.7-fold factor. When cells are 
treated with DNR, MVs<0.65 μm have a weak significant procoagulant effect 
as measured by either the peak or the lagtime in contrast with MVs<0.65 μm 
derived from untreated cells. ETP is not affected by the treatment (Figure 
22).  
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Figure 21. Thrombin generation curves and histograms of lagtime and peak parameters 
(n=6). A) Impact of DNR treatment on procoagulant activity of NB4 cells. B) Impact of DNR 
treatment on procoagulant activity of MVs<0.65μm derived from NB4 cells. Data with 
significant difference in comparison to untreated condition are indicated with * (p<0.05). 
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Figure 22. Thrombin generation curves and histograms of lagtime and peak parameters 
(n=6). A) Impact of DNR treatment on procoagulant activity of HL-60 cells. B) Impact of 
DNR treatment on procoagulant activity of MVs<0.65μm derived from HL-60 cells. Data 
with significant difference in comparison to untreated condition are indicated with * 
(p<0.05). 
 
5.4.5 PCA characterization by thrombin generation for acute promyelocytic 
leukaemia cells lines (NB4 and HL-60) treated with tissue factor 
activator (HgCl2) 
As seen in Figure 23.A, NB4 cells have a high procoagulant activity and 
HgCl2 does not alter this effect. Figure 23.B. shows that HL-60 cells have a 
procoagulant activity which is in turn increased by the addition of the TF 
activator HgCl2, whatever the considered paramete. Lagtime of HL-60 treated 
is reduced 1.3-fold, ETP and peaks are increased 1.5- and 1.6- fold 
respectively (Figure 23.B). 
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Figure 23. Thrombin generation curves and histograms of lagtime and peak parameters 
(n=6). A) Thrombin generation experiments. Curve data are presented as mean with n=6. 
Effect of TF activator (HgCl2) on NB4 cells thrombin generation activity. B) Effect of TF 
activator on HL-60 thrombin generation activity. Data with significant difference in 
comparison to untreated condition are indicated with * (p<0.05). 
 
5.5 Discussion 
 
Since early mortality in leukaemia chemotherapy is often due to the high rate 
of bleeding complications, investigation of the pathogenesis of the 
haemostatic dysfunction in these diseases becomes a matter of high priority 
(Kwaan and Rego 2010). Cancer cells release procoagulant MVs into plasma 
(Haubold, Rink et al. 2009). Thrombosis and disseminated intravascular 
coagulation (DIC) complicate acute leukaemias either before or after 
chemotherapy suggesting that malignant cells release a procoagulant activity 
leading to increased thrombin activity. Moreover, in acute promyelocytic 
leukaemia, this exacerbated coagulation tends to disappear after all-trans 
retinoic acid (ATRA) therapy, a drug allowing these peculiar malignant cells 
to maturate. In order to check if hypercoagulation states encountered in acute 
leukaemias and especially in acute promyelocytic leukaemias originate from 
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Tissue Factor-bearing MVs, NB4 and HL60, two APL cell lines, were tested 
in vitro for their ability to produce MVs and increase TF activity and thrombin 
generation. 
This study shows the capacity of NB4 cells to produce MVs. These MVs are 
shed by the plasma membrane of NB4 cells as illustrated by electron 
microscopy. Our data clearly illustrate the steps of MVs’ generation, and 
confirm the bilayer ultrastructure of their membrane. MVs derived from NB4 
cells have a size comprised from 90 to 832 nm with a large majority from 200 
to 400 nm. Consequently, they should not be considered as exosomes, in 
accordance with previous studies (Castellana, Toti et al. 2010, Leong, Podor 
et al. 2011). However, these dimensions are measured on slices and may be 
underestimated since the vesicles are not always cut through their equators. 
On the other hand, as observed with manufactured nanoparticles (Tenzer, 
Docter et al. 2011), MVs may be associated with proteins (“corona effect”) 
during TEM preparation leading to a overestimation of the size. 
By flow cytometry, MVs derived from NB4 cells are characterized by their 
expression of TF and phosphatidylserine according to other studies (Koyama, 
Hirosawa et al. 1994, Marchetti, Diani et al. 2012) . Flow cytometry shows 
that cells and MVs express TF. NB4 cells have been previously described 
with a high expression of TF (Marchetti, Diani et al. 2011) By TGA we show 
that most of the procoagulant activity of NB4 cells comes from MVs between 
100nm and 650nm. This result confirms the production of procoagulant MVs 
by leukemic cells. By different filtrations, and the use of inhibition of PL, we 
demonstrate that MVs with procoagulant activity derived from NB4 cells 
have a size higher than 100 nm, and that the MV procoagulant activity is 
linked to the expression of TF and PL mainly phosphatidylserine. 
Surprisingly, HL-60 cells have not the same procoagulant profile. Their 
procoagulant activity is associated to the cells themselves and no PCA is 
observed when cells are filtered through 0.65µm membrane. These cells are 
sensitive to all-trans retinoic acid (ATRA) therapy in contrast to NB4 cells. 
The treatment by DNR of both cells types increases the procoagulant activity 
of cells. Moreover, the procoagulant activity of MVs is also increased when 
cells are treated, which can strengthens our hypothesis on major implication 
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of MVs derived from leukemic cells in procoagulant state of patient with or 
without treatment.  DNR treatment affects principally the TGA peak 
parameter, which is the most sensitive to PL. This is in accordance with 
another study which shows an increased procoagulant activity after DNR 
treatment (Zhu, Guo et al. 1999). DNR-treated cells have an increased 
expression of phosphatidylserine on surface and this could lead to tissue 
factor activation (Langer, Amirkhosravi et al. 2004). The phospholipid 
composition of MVs could be different when there are generated by treated 
or untreated cells. This increase of MVs’ PCA after treatment could be due to 
the same causes of the increased PCA of whole cells. When comparing cells 
treated by DNR and by TF factor activator there is a difference only for HL-
60 cells. However TF activation has a weak impact on TGA’s peak. This 
result is in accordance with the hypothesis that the increased peak by DNR is 
mostly due to the overexpression of phosphatidylserine. Moreover, when HL-
60 cells are treated with TF activator the lagtime is reduced after DNR 
addition which suggests that TF is activated by phosphatidylserine expression 
after DNR treatment (Langer, Amirkhosravi et al. 2004). 
This study suggests the implication of TF-MVs derived from leukemic cells 
in inducing an increased procoagulant state. Moreover, the characterization 
of leukemic TF-MVs should be a useful biomarker for thromboembolism 
prediction (Zwicker, Liebman et al. 2012). Speculatively, it seems that MVs 
derived from leukemic cells could have a bad prognostic outcome since they 
could be related to ATRA resistance of leukemic cells for example. 
Szczepanski et al. also showed that MVs derived from cancer cells can induce 
an immune suppression and the demise of antitumor CD8(+) effectors T cells, 
thus contributing to tumour escape (Wieckowski, Visus et al. 2009, 
Szczepanski, Szajnik et al. 2011). These advances in MVs function comforts 
us in considering MVs derived from cancer cells as a key component in cancer 
disease. 
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6 Plasmatic procoagulant EVs from AL patients as 
potential biomarker of procoagulable state. 
 
Article in preparation 
Microvesicles are a potential biomarker for DIC and thrombosis in 
acute leukemic patients. 
 
Gheldof Damien, Dogné Jean-Michel, Graux Carlos, George Fabienne, Sonet 
Anne, Chatelain Bernard, Mullier François, Chatelain Christian 
Our hypothesis that leukemic cells can shed procoagulant EVs is proved in 
vitro. In this research we try to confirm this hypothesis in vivo. We try to 
confirm that patient with AL who suffer from thromboembolic disease have 
in their plasma an increased PCA due to the presence of EVs. We also study 
if the PCA of plasmatic EVs came from their procoauglant phospholipids 
surface or/and tissue factor anchored in EVs.  
In order to study plasmatic EVs from leukemic patients, we tightly work with 
Biobank of CHU Dinant Godinne. We set up in January 2012 a protocol to 
take blood from acute leukemic patient in order to respect restrictive pre-
analytic conditions associated to EVs PCA study (Mullier, Bailly et al. 2013). 
We work on plasmatic EVs before and after treatment induction in order to 
study the chemotherapy impact on plasmatic EVs PCA and in order to 
confirm that chemotherapy can induced a procoagulant state by increased 
EVs PCA.  
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6.1 Abstract 
 
Background: Hypercoagulable state is a common complication of patients 
with malignancies. Recent studies suggest that extracellular vesicles (EVs) 
procoagulant activity (PCA) may have a major role in venous 
thromboembolism or disseminated intravascular coagulation (DIC) in acute 
leukaemia.  
Aims: The aim is to study the impact of EVs from leukemic patient on 
thrombin generation and if EVs-PCA could be a potential biomarker to 
evaluate hypercoagulable state in patient with acute leukaemia.  
Methods: Blood samples from 38 patients with acute leukaemia newly 
diagnosed were obtained at Day-0 (before treatment), D-3 and D-7 (3 and 7 
days after treatment). Extracellular vesicles were isolated and concentrated 
by ultracentrifugation. EVs-PCA and EVs-tissue factor activity was measured 
a commercial bio-immunoassay (Zymuphen MP-TF®), respectively.  
Results: Among acute leukemic patients, 3 patients have an increased EVs 
PCA at D-0 and 2 of them developed a thrombotic event. The remaining 
patients without thrombotic events do not show an increased EVs-PCA. One 
patient has an increased extracellular vesicles procoagulant activity at D-3 
and developed a DIC at D-5. Three patients have an increased EVs-tissue 
factor activity (>2pg/ml), among these, two developed a thrombotic event and 
one had haemorrhage. A plasma from patient with induced DIC has no 
increased extracellular vesicles tissue factor activity from D-0 to D-7 
(<2pg/ml).  
Conclusions: The results suggest a strong association between 
hypercoagulable state and extracellular vesicles procoagulant activity. 
Moreover, extracellular vesicles procoagulant activity could have a predicting 
value for venous thromboembolism disseminated intravascular coagulation in 
patients with acute leukaemia and especially for excluding patient without 
risk of thrombotic events. .  
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Abbreviations: venous thromboembolism (VTE) disseminated intravascular 
coagulation (DIC) acute myeloblastic leukemia (AML) acute lymphoblastic 
leukaemia (ALL) extracellular vesicles (EVs) tissue factor (TF) procoagulant 
phospholipids (PL) procoagulant activity (PCA) thrombin generation assay 
(TGA) body mass index (BMI) before treatment (D-0) 3 days after treatment 
(D-3) 7 days after treatment (D-7) normal pooled plasma (NPP) 
ultracentrifugation (UC) standard deviation (S.D.) healthy volunteers control 
(CTL) tissue factor pathway inhibitor (TFPI) negative predictive value (NPV) 
positive predictive value (PPV) 
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6.2 Introduction 
 
Despite the remarkable improvement of survival in patients with acute 
leukaemia for the past twenty years, a significant early mortality remains due 
to bleeding and thrombotic complications (Ku, White et al. 2009, Kwaan and 
Rego 2010). Hypercoagulable states such as venous thromboembolism (VTE) 
and disseminated intravascular coagulation (DIC) are highly prevalent 
complications of cancer and anticancer therapy (Tesselaar, Romijn et al. 
2007, Davila, Amirkhosravi et al. 2008, Khorana 2013, Khorana, Dalal et al. 
2013). Among patients with acute myeloblastic leukaemia (AML), the 
incidence of VTE is 5.2%, and among patients with acute lymphoblastic 
leukaemia (ALL), the incidence of VTE is 4.5% in the first two years of 
disease (Ku, White et al. 2009). However, the underlying mechanisms behind 
a hypercoagulable state are not yet fully understood. Multifactorial causes 
include physical immobility, chemotherapy adverse effects (Pollyea, Kohrt et 
al. , Schneider, Van Dreden et al.) and the overexpression of several 
procoagulant substances by cancer cells (cytokines, cysteine protease, tissue 
factor…) (Davila, Amirkhosravi et al. 2008). Previous studies have 
demonstrated that cancer cells and leukemic blast can shed extracellular 
vesicles (EVs) harbouring tissue factor (TF-EVs) (Davila, Amirkhosravi et 
al. 2008, Gheldof, Mullier et al. 2014). Tissue factor, the most potent initiator 
of the coagulation cascade, plays a critical role in haemostasis (Davila, 
Amirkhosravi et al. 2008, Petropoulou, Gerotziafas et al. 2008, Mackman 
2009, Mackman and Taubman 2009, Diego-Garcia, Peigneur et al. 2013).  
EVs are considered as key components of the haemostatic system. These are 
small membrane vesicles shed from normal and/or tumour cells following 
activation or apoptosis. They can be captured in the developing thrombus and 
lead to thrombin generation by expression of PL and TF (Mackman 2004, 
Furie and Furie 2008) (Figure 24). The co-expression of TF and procoagulant 
phospholipids (PL) such as phosphatidylserine on the TF-EVs is highly 
prothrombotic. We and others have previously demonstrated that acute 
leukemic cells as promyelocytic cells generate EVs with TF-PCA (Figure 24) 
(Zhou, Shi et al. 2010, Gheldof, Mullier et al. 2014, Thaler, Pabinger et al. 
2014). 
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Figure 24. Activation of coagulation cascade by EVs derived from leukemic cells. Activated 
TF and procoagulant phospholipids on EVs surface activates tissue factor pathway of 
coagulation cascade. Complex TF-factor VII activates factor X which activates prothrombin. 
These activations need negatively charged phospholipids (PLs) and Ca++. Tissue factor 
pathway inhibitor (TFPI) is present in plasma and inhibits the complex TF/FVIIa/FXa.  
 
EVs concentration and surface antigens can be estimated by several analytical 
technics such as flow cytometry, atomic force microscopy, transmission 
electron microscopy and dynamic light scattering. However, they are all 
associated with multiple limitations reviewed elsewhere (Waisman, Danino 
et al. 2007, Tatischeff, Larquet et al. 2012, Issman, Brenner et al. 2013). 
Therefore, we mainly focused on the measurement of the EVs procoagulant 
activity using adapted thrombin generation assay (TGA) and a specific bio-
immunoassay measuring TF-activity (Gheldof, Hardij et al. 2013, Gheldof, 
Mullier et al. 2013, Thaler, Pabinger et al. 2014). 
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The primary aims of this study was to evaluate the PCA of plasma EVs from 
patients with AL by thrombin generation assay and to study the correlation 
between EVs PCA and hypercoagulable state. The second objective was to 
determine the impact of chemotherapy on EV-PCA and the contribution of 
TF activity in EV-PCA by a bio-immunoassay measuring TF-activity (Zhou, 
Shi et al. 2010). 
6.3 Methods 
 
6.3.1 Laboratory and clinical data from patients with acute leukaemia 
A total of 38 consecutive patients newly diagnosed with AL following the 
French-American-British criteria were included in this study (Walter, Othus 
et al. 2013). All patients signed the informed consent following the 
requirements of local ethical committee (Ethical committee approval number 
B039201212954). The study included 17 white females and 13 white males 
ranging from 17 to 76 years old with body mass index (BMI) between 16 and 
34 kg/m2. Patient’s characteristics are summarized in table 2. The D-dimer 
analysis was performed on STA-Liatest DDi (LI) (Diagnostica Stago, 
Asnières-sur-Seine, France). Thrombin time, activated partial thromboplastin 
time and prothrombin time were performed on STA-R (Diagnostica Stago, 
Asnière sur Seine, France). Platelet count, leucocyte count and haemoglobin 
measurement were performed on XE-2100 (Sysmex, Kobe, Japan). The 
measurement of EVs-TF activity was performed with a bio-immunoassay 
zymuphen MP-TF (Aniara manufactured by HYPHEN BioMed, Neuville sur 
Oise, France). Thrombosis and haemorrhage diagnosis are performed based 
on routine standard clinical practices. Overt DIC diagnosis was performed 
according to the scoring system of the Scientific and Standardisation 
Committee on DIC of the International Society on Thrombosis and 
Hemostasis (Taylor, Toh et al. 2001, Knobl 2005). 
6.3.2 Blood sampling 
Blood was taken by venipuncture in the antecubital vein and collected into 
0.109 M sodium citrate (9:1 v/v) tubes (Venosafe®, Terumo, Leuven, 
Belgium) using a 21-gauge needle (Terumo). Samples were obtained from 44 
patients before treatment (D-0), 3 days after treatment (D-3) and 7 days after 
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treatment (D-7) (17)(Schultz, Massing et al. 1997) since persistence of blood 
and bone marrow blastosis at day 7 is of poor prognosis. So day 3 and day 7 
represent reasonable times of estimating action of chemotherapy on blast cells 
and residual normal cells, before aplasia. Platelet-free plasma was obtained 
by a first centrifugation at 2,500g for 15min at room temperature (Heraeus 
Multifuge 1S-R, Sysmex Benelux, Etten-Leur, The Netherlands) with a light 
brake only, within one hour after sampling. The platelet-poor plasma was 
collected and transferred into a polypropylene haemolysis tube with a 
micropipette. Aspiration was stopped 1cm above the buffy-coat while 
avoiding the buffy-coat. Platelet-poor plasma was centrifuged a second time 
at 2,500g for 15min at room temperature. The platelet-free plasma was 
collected into a fresh tube using a micropipette, while leaving about 100μl at 
the bottom of the tube. Plasmas samples are frozen in liquid nitrogen and 
stored at -80°C.   
6.3.3 Isolation and concentration of EVs for thrombin generation assay 
Extracellular vesicles from patient plasma or NPP are isolated by 
ultracentrifugation (UC). 400μl of frozen plasma were thawed at 37°C and 
centrifuged at 100,000g for 90min at 4°C. The pellet of EVs is re-suspended 
in 60μl plasma free EVs (supernatant after UC) to concentrate EVs 6.7 times.  
6.3.4 Preparation of normal-pooled plasma and platelet-free plasma 
Normal pooled-plasma was prepared as previously described (Robert, 
Ghiotto et al. 2009, Mullier, Bailly et al. 2013). Blood was taken from forty-
two healthy individuals, after information consent signed, by venipuncture in 
the antecubital vein and collected into 0.109M sodium citrate (9:1 v/v) tubes 
(Venosafe®, Terumo, Belgium) using a 21-gauge needle (Terumo, Belgium). 
Platelet-free plasma was obtained by a first centrifugation at 2,500g for 15min 
at room temperature (Heraeus Multifuge 1S-R, Sysmex Benelux, Etten-Leur, 
The Netherlands) with a light brake only, within one hour after sampling. 
Platelet-poor plasma was collected and transferred into a polypropylene 
haemolysis tube with a micropipette. Aspiration was stopped 1cm above the 
buffy-coat while avoiding the buffy-coat. Platelet-poor plasma was 
centrifuged a second time at 2,500g for 15min at room temperature. Platelet-
free plasma was collected into a fresh tube using a micropipette, while leaving 
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about 100μl at the bottom of the tube. Plasmas samples are frozen in liquid 
nitrogen and stored at -80°C.   
6.3.5 Measurement of the EVs procoagulant activity (PCA) by thrombin 
generation assay (TGA) 
PCA was measured by TGA according to a modified version of the method 
developed by Hemker (Hemker, Giesen et al. 2002) . In a 96-well round 
bottom plate, 20µL of pre-warmed plasma EVs was added to one well and 
20µL of prewarmed calibrator, i.e. 60 nM alpha2M-thrombin complex to 
another well; 80µL of plasma was added to both wells. Calcium (Ca++) was 
added together with the substrate at the start of the measurement (Fluka 
Solution). Concentrated EVs from patient samples, healthy donors and NPP 
were used as the source of TF and PL. 80µl of NPP and 20µl of concentrated 
EV were mixed.  
Readings were performed in a microtiter plate fluorometer (Fluoroscan 
Ascent, Thermolabsystems, Helsinki, Finland), at 37°C. Briefly, the plasma 
clotting was triggered by the addition of 20μl fluorogenic substrate/calcium 
chloride buffered solution at 37◦C. A calibration curve was also performed 
for each blood draw using 80μl of NPP and 20μl of thrombin calibrator and 
20μl of substrate/calcium chloride-buffered solution. The reaction of 
substrate hydrolysis was monitored on a microplate fluorometer Fluoroskan 
Ascent FL (Thermo Labsystems) with a 390/460-nm filter set 
(excitation/emission) using the Thrombinoscope® software version 3.0 
(Synapse BV). The thrombin generation curves and all parameters (lagtime, 
peak, endogenous thrombin potential and time to peak) were calculated using 
software Thrombinoscope®. The results were expressed as means ± standard 
deviation (S.D.) in percent in comparison of PCA of EVs from healthy 
volunteers control (CTL) which represent 100%.  
In order to increase thrombin generation sensitivity to TF-EVs PCA, plasma 
TFPI was inhibited with a monoclonal antibody (ADG4903 American 
Diagnostica Gmbh) against Kunitz Domain I of human TFPI. Before TGA 
analysis, NPP was incubated 15min at 37°C with antibody at 10µg/ml in final 
concentration, before performing the experiment. This protocol was 
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described previously by Gheldof  et al. (Robert, Ghiotto et al. 2009). All the 
experiments were performed in triplicate. 
6.3.6 Measurement of EVs-TF activity 
The measurement of EVs-TF activity was performed with Zymuphen MP-
TF® kit according to the manufacturer’s instructions. Briefly, 20 µl of patient 
plasma with MP-TF-assay enhancer were introduced into the wells of a 
microplate coated with a murine monoclonal antibody, specific for human TF 
(10H10), and which does not interfere with TF activity. Following an 
overnight incubation and an automated washing step, washing solution was 
immediately introduced into the wells. Then, factor VIIa and factor X were 
added. The TF-FVIIa complex forms and subsequently activates factor X into 
activated factor X (FXa). In a third step, a specific substrate for FXa was 
introduced and reacts with FXa and produces a yellow color. The absorbance, 
recorded at 405nm on a spectrophotometer, is directly proportional to the 
amount of MP-TF present in the sample. Normal plasmas are found below 
2pg/ml of EV-TF. 
6.3.7 Statistics 
Comparison between different conditions was performed using Wilcoxon test 
on GraphPad Prism® software (version 5.01). 
6.3.8 Data Analysis 
The sensitivity, speciﬁcity, negative predictive value (NPV) and positive 
predictive value (PPV) were calculated using Medcalc software (version 
10.4.8) (Gent, Belgium). 
 
6.4 Results 
 
 In this study, lagtime which corresponds to the initiation of clot formation 
(min) and thrombin peak which corresponds to maximal concentration of 
active thrombin (nM)) are the most relevant parameters to discriminate 
patients with or without thrombotic events (data not shown).  
At D-0, 3 out of the 38 patients had no significantly increased ration in 
comparison to CTL (100%). All of these patients did not develop any 
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thrombotic event. Among the 3 patients with a significant increase of ratio, 
patients #11 and #17 had an hypercoagulable state   and had D-Dimer levels 
at >6000 ng/ml and 1,370 ng/ml respectively. Patient #11 developed a DIC 
and patient #17 developed a venous thromboembolism in kidney. Patient #9 
did not develop any clinically relevant thrombotic event. Patient with 
increased EVs PCA and without clinical thrombotic event had a D-Dimer 
value of 630 ng/mL. Only EVs from patient #9 had a reduced lagtime and 
increased peak with a ratio Peak%/Lagtime% over 1.7 without clinical 
thrombotic event (figure 25). 
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Figure 25. Procoagulant activity of EVs from patient at diagnosis (D-0) before any treatment, 
ratio between peak and lagtime. Peak (%) /Lagtime (%). CTL used represent 100% Peak/ 
100% Lagtime.  
 
 At D-3, patient #16 had a ratio Peak%/Lagtime% of 1,76 and experienced 
DIC at D-5 with D-Dimer level higher than 1000 ng/ml. Patient #17 with ratio 
Peak%/Lagtime% at 1,77 was diagnosed with venous thromboembolism in 
kidney at D-0. (Figure 26). The combination of peak and lagtime parameter 
allows distinction between thrombotic and non-thrombotic populations 
(Figure 26).  
109 
 
Peak/Lag D-3
P
e
a
k
%
/L
a
g
%
0
1
0
2
0
3
0
4
0
5
0
6
0
8
0
8
0
9
1
0
1
1
1
2
1
3
1
5
1
5
1
6
1
7
1
8
1
9
2
0
2
1
2
2
2
3
2
4
2
5
2
6
2
7
2
9
3
0
3
1
3
2
3
3
3
4
3
5
3
6
3
7
3
8
C
T
L
0
2
4
6
8
10
Figure 26. Procoagulant activity of EVs from patient 3 days (D-3) after induction of 
chemotherapy, ratio between peak and lagtime. Peak (%) /Lagtime (%).CTL used represent 
100% Peak/ 100% Lagtime. 
 
At D-7, none of the patients showed a decreased lagtime. Only patient #11 
had a 38% augmentation in the peak in comparison to CTL. However the ratio 
Peak%/Lagtime% is under 1.7 (Figure 27). The NPV of this combination on 
the tree times points was 100% (95% CI: 89.6 to 100%) and the PPV was 
80.0% (95% CI: 20.3% to 95.9%). The sensitivity and specificity were 100% 
(95% CI: 30.5% to 100%) and 95.72% (95% CI: 85.0% to 99.5%), 
respectively. 
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Figure 27. Procoagulant activity of EVs from patient, 7 days (D-7) after induction of 
chemotherapy, ratio between peak and lagtime. Peak (%) /Lagtime (%).CTL used represent 
100% Peak/ 100% Lagtime. 
 
Biological parameters used in Khorana score risk model at D-0 are displayed 
in Figure 28. Based on these parameters, patients who developed thrombotic 
events cannot be dissociated from patients without thrombosis. Among 
twenty patients, none had a platelet count higher than 350.000/μl and no one 
with thrombotic event had a haemoglobin concentration below 10 g/dl (Table 
2). For leucocyte count, 8 patients had leukocyte count higher than 11.000/μl; 
the cut off proposed in the Khorana score model (Khorana and Connolly 
2009). Among these patients, two had a hypercoagulable state (VTE in kidney 
and induced DIC five days after induction of the treatment).  
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Figure 28. Biological parameters used in Khorana score risk model at diagnosis day. One 
point is attributed when platelets count> 350 G/l; Hemoglobin level< 100 g/l ; Leucocytes 
count > 11 G/k ; D-Dimer > 1.44 µg/mL  
 
The activity of EVs-TF was determined by Zymuphen MP-TF®. These data 
show a high EVs-TF activity (>2pg/ml) in patient #7 who had haemorrhage 
(epistaxis, buccal petechiae, digestive bleeding), patient #11 who developed 
a DIC and #17 who developed a kidney thrombosis. Patient #16 who 
developed an induced DIC 5 days after treatment induction had no increased 
EVs-TF activity.(Figure 29) The NPV of this bioassay was 97.1% (95% CI: 
85.3 to 99.5%) and the PPV was 66.7% (95% CI: 11.6% to 94.5%). The 
sensitivity and specificity were 66.7% (95% CI: 11.6% to 94.5%) and 97.1% 
(95% CI: 85.0% to 99.5%), respectively. 
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Figure 29. a) EVs TF activity in pg/ml in plasma of each patient at diagnosis day b) EVs-TF 
activity of patient #11, #16 and #17  with thrombotic event (DIC, induced DIC, kidney 
thrombosis) during seven days after induction of chemotherapy.   
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6.5 Discussion 
 
Early mortality in acute leukaemia is partly due to haemostatic dysfunctions 
such as bleeding, thrombosis or DIC.  The underlying mechanisms are still 
not fully understood. In this study, we aimed at investigating the implication 
of EVs in thrombosis. The second objective is to determine the contribution 
of TF activity in EV-PCA and the impact of chemotherapy on EV-PCA 
(Zhou, Shi et al. 2010). 
 
Our results at diagnosis days (D-0) show that EVs from three patients have a 
higher potential to support thrombin generation in comparison to healthy 
donors. EVs from these patients have a significant impact on TGA 
parameters, such as lagtime reduction and increased peak (Owens and 
Mackman 2012). This increased PCA could be associated to an increase of 
EVs number and/or of PCA of EVs by expression of TF or procoagulant 
phospholipids (Li, Yu et al. 2010, Lima, Oliveira et al. 2011).  
 
Interestingly, two out of these three AML patients had hypercoagulable state 
with DIC and thrombotic event at diagnosis. Patients #11 developed an overt 
DIC at study inclusion (Taylor, Toh et al. 2001, Knobl 2005), patient #17 
developed a VTE in Kidney and patient #143 developed a DIC. At diagnosis, 
patients without thrombotic event had a similar or weaker PCA in their EVs 
than those from healthy controls. Only one patient (#9) had an increased PCA 
of EVs in comparison to CTL and does not have thrombosis. 
 
The analysis of PCA of EVs from patients #16 at D-3 shown a slight increase 
of ratio in comparison to CTL and this patient developed a DIC 5 days after 
treatment induction. The ratio lagtime/peak shows the distinction between 
PCA of EVs from this patient and other patients. This increased EVs PCA 
can be associated to chemotherapy induction. As previously shown in several 
studies, chemotherapy increases procoagulant state and can rise the 
procoagulant activity of EVs or the EVs shedding from cancer cells (Khorana 
and Connolly 2009, Van Aalderen, Trappenburg et al. 2011, Gheldof, Mullier 
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et al. 2013). Chemotherapy could induce externalisation of 
phosphatidylserine on the cell surface and subsequently lead to activation of 
TF (Langer, Amirkhosravi et al. 2004, Tormoen, Recht et al. 2013, Langer 
and Ruf 2014). 
 
Patient #11 with AML M3 has EVs PCA similar to healthy subject at D-3. 
This reduction of EVs PCA between D-0 and D-3 was confirmed by the bio-
immunoassay and could be due to ATRA treatment at D-0. ATRA is well 
known to reduce the expression of TF by induction of differentiation 
leukemic cells (Zhang, Hu et al. 2007, Marchetti, Russo et al. 2011).  
 
Seven days after treatment, only one patient had an increased EVs fraction 
PCA. This patient developed a DIC at diagnosis. This increased EVs-PCA 
could be due to treatment by cytarabine and idarubicine at D-3 (Tormoen, 
Recht et al. 2013). 
 
The Zymuphen MP-TF® confirms the results of TGA for two patients. 
However, issue of patient #16 cannot be detected by this test. This suggests a 
lack of sensitivity for Zymuphen MP-TF® in comparison to TGA (Hellum, 
Ovstebo et al. 2012) (Gheldof, Chatelain et al. 2014). 
 
This study strongly supports the role of EVs in haemostatic disorder. EVs 
produced by leukemic cells could have a major role in thrombosis 
development and hypercoagulable state in patient with acute leukaemia. In 
addition to their contribution in haemostatic disorder, EVs could be 
considered as biomarker for the risk of thrombosis. Currently, only the 
Khorana risk score is available to predict thrombosis in cancer patient. It is 
based on neutrophil count, platelet count, haemoglobin, D-dimers and body 
mass index is only available for patients with solid tumours (Khorana and 
Connolly 2009). However, as shown in Table 1 some of the parameters are 
irrelevant in AL since neutrophil count, platelet count and haemoglobin 
concentration are affected by the disease and their treatments.  There is a need 
to develop specific biomarkers which could predict the risk of 
thromboembolism or DIC in AL patients. 
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In this context, adapted TGA with an increased sensitivity to TF-EVs PCA 
(Gheldof, Mullier et al. 2013) provides an estimation of PCA. This is more 
relevant to estimate the overall procoagulant activity of EVs rather than the 
more specific estimation of MP-TF activity (Gheldof, Chatelain et al. 2014). 
The combination of lagtime and peak parameters provides promising support 
for identifying high, low and perhaps no risk patients for developing with 
higher sensitivity, negative predictive value and specificity than Zymuphen 
MP-TF® (Figures 25, 26 and 29) 
 
This pilot study has some limitation due to the limited number of patients and 
requires further confirmation on a larger population (Mullier, Bailly et al. 
2013). Due to this limitation, no stratification was possible to assess the 
impact of the different treatment protocols.  
 
In conclusion, PCA of EVs should be further developed as marker of the 
hypercoagulable state in AL and especially as a way to detect patients which 
can benefit from anticoagulation despite their thrombocytopenia.  
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Table 2. Patient’s characteristics at diagnosis. FAB: French-American-British; ALL: acute lymphoblastic leukaemia; AML: acute 
myeloblasitc leukemia; PLT: platelet; Hgb: Haemoglobin; Fib: FibrinogenAPTT: activated partial thromboplastin time; PT: 
prothrombin time; DIC: disseminated intravascular coagulation. 
Patient Age, sex 
Diagnosis 
(FAB 
classificatio
n) 
Hgb (g/dl) 
Leucocytes 
(X1000/µl) 
PLT 
(x1000/µL) 
Fib 
(ng/µL) 
APTT 
(sec) 
PT 
(%) 
D-dimer 
(ng/mL) 
Haemostatic 
complication 
Treatment 
CTL   12.0-15.8 3.9-9.9 150-400 180-400 26-38 75-
100 
<500   
1 17, male ALL-B 9.6 17.94 24 505 42.9 94 ND petechiae Daunorubicin 
2 70, female AML M2 8.2 3.92 195 434 31 100 ND none Aracytine+ Daunorubicin 
3 76, female AML M0 9,2 1.78 119 291 32.9 95 ND none VIDAZA(Raj and Mufti 2006) 
4 56, female AML M2 9.7 8.71 32 301 25.3 94 4510 none Aracytine + Idarubicin 
5 53, female AML M2 6.0 20.69 7 608 31.4 73 2380 Haemorrhage Aracytine + Idarubicin 
6 55, male ALL-B 10.8 0.79 111 392 26.1 81 ND none Idramycin + Vincristin 
7 64, male AML M5 8.9 76.24 9 315 30.2 89 ND Haemorrhage none 
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8 21, male ALL-B 11,1 3.5 19 459 31.4 57 >6000 none Fralle 2000(Mitchell, Lambers et al. 
2010) 
9 48, female ALL-B 8.7 0.29 27 276 30.6 93 630 none Oncovin + Asparaginase 
10 49, female AML M4 11,7 6.13 167 316 31.2 86 ND none Aracytine + Idarubicin 
11 34, female AML M3 9 6.36 25 84 26.4 73 >6000 DIC ATRA D-0 + Aracytin/Idarubicin D-3 to 
D-9 
12 47, female AML 6.7 6.07 40 ND 34 75 ND none Aracytine + Idarubicin (Hovon 
102)(Cornelissen, van Putten et al. 
2007) 
13 70, female AML M6 8.7 1.8 59 562 28 98 500 none POLO-AML-2 (Hartsink-Segers, Exalto 
et al. 2013) 
14 57, female AML M0 9 13.88 125 667 29 81 ND Haemorrhage Aracytine + Idarubicin 
15 34, female ALL-T 11.1 15.03 64 420 27.1 98 360 none GRAALL 2005(Maury, Huguet et al. 
2010) 
16 58, male AML M1 9.6 28.89 12 245 27.9 80 >6000 Induced DIC 
at D-5 
HOVON 102(Cornelissen, van Putten et 
al. 2007) 
17 47, male AML M5 14.7 80.42 56 382 30.8 68 1370 kidney 
thrombosis 
HOVON SAKK AML 102(Cornelissen, 
van Putten et al. 2007) 
18 36, male AML 7.7 1.8 71 364 30.1 73 >6000 none HOVON-SAKK AML 102(Cornelissen, 
van Putten et al. 2007) 
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19 71, male AML M2 14.4 2.68 85 402 34 78 ND none HOVON 103 AML/SAKK(Cornelissen, 
van Putten et al. 2007) 
20 43, male AML M0 9.1 49.78 145 887 32.9 92 360 none HOVON 102(Cornelissen, van Putten et 
al. 2007) 
21 60, male ALL-B 13.7 21.86 69 520 29.2 94 4680 non Daunorubicin 
22 63. male AML M1 13.7 3.07 243 ND 31.2 82 ND none HOVON SAKK AML 102(Cornelissen, 
van Putten et al. 2007) 
23 34, male ALL-B 12.8 6.44 48 384 38.9 87 1500 none GRAALL 2005(Maury, Huguet et al. 
2010) 
24 45, female AML M4 9.2 1.98 56 378 32 76 880 none Aracytine+ Idarubicin 
25 73, female AML 9.4 7.94 8 280 29.2 62 2270 Haemorrhage 
 
POLO-AML-2 (Hartsink-Segers, Exalto 
et al. 2013) 
26 58, female ALL-B 13.2 54.9 283 449 32 100 350 none GRAALL 2005(47) 
27 57, male AML 9.8 6.09 75 197 23 59 >6000 none HOVON 102(45) 
28 63, male AML M2 7 2.12 26 605 33.6 78 1140 none HOVON SAKK AML 102(Cornelissen, 
van Putten et al. 2007) 
29 58. female AML M4 8.6 1.22 26 498 ND 73 ND none HOVON 102(45) 
30 65, male AML M6 9.3 1.58 92 375 33.1 88 350 none HOVON SAKK AML102(45) 
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31 65, male  AML M6 9.3 1.58 92 375 33.1 88 350 none HOVON SAKK AML102(45) 
32 65, male  AML M6 9.2 1.22 55 552 33.4 87 ND none HOVON SAKK AML 132 
33 41, male ALL-B 9.7 1.24 58 ND 21.2 83 ND none GRAALL 2005[48] 
34 44, female AML M2 8.3 3.77 142 375 27.5 71 600 none HOVON SAKK AML 132 
35 73, female AML M3 8.7 0.88 45 513 31.4 99 2990 none ATRA + Idarubicin 
36 73, male AML M2 12.6 1.36 169 488 32.5 90 680 none Hovon 103 AML/SAKK[46] 
37 60, female AML M6 9.6 1.9 86 270 27.9 77 ND none HOVON SAKK AML 132 
38 55, male AML 9.8 1.07 31 268 30.6 92 550 none HOVON SAKK AML 132 
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7 General discussion and future perspectives 
 
The prevention of hypercoagulable state in cancer patient is a major goal to 
reduce the related death, the arrest of chemotherapy and the VTE-associated 
costs. As example, the mean cost of VTE management ranges from 7,700$ to 
16,000$ (Bullano, Willey et al. 2005, Spyropoulos and Lin 2007, Lefebvre, 
Laliberte et al. 2012) with at least one half of the expenditure being 
attributable to hospitalization. In cancer patient, VTE associated costs can 
reach 20,000$ (Elting, Escalante et al. 2004). 
 The early death of leukemic patient by hypercoagulable complication such 
as VTE and DIC is still a major problem and it can be suppressed by all 
anticoagulant therapy currently available. Preventing thromboembolic 
complications in AL patients is not an easy task since the risk of haemorrhagic 
complications is also high due to the presence of thrombocytopenia in most 
cases (Guzman-Uribe and Vargas-Ruiz 2015). The only way to safely prevent 
thrombotic events in AL is via a better understanding of coagulation disorder 
related to leukaemia. The study of underlying mechanisms can lead to find 
new potential biomarkers to overcome the present score model for thrombosis 
and cancer patient, which is not suitable for AL patient. 
Several studies suggest that EVs bearing TF are implicated in thrombosis 
related to cancer in vivo. (Morel, Toti et al. 2006) An extensive literature 
exists on the perturbation of EVs numbers and activity in various diseases. 
(Zwicker, Trenor et al. 2011). The circulation of active TF associated with 
EVs has been considered as a promising biomarker to predict the risk of VTE 
in cancer patients. In order to study EVs in vitro or to use EVs as biomarkers 
for clinical laboratory, several methods are required to overcome limitations 
of each one and provide a better characterization of EVs.  
In this work we started by identifying several useful methods to study EVs. 
The combination of FCM, TEM and TGA allows studying antigens, the 
activity of TF and PLs on EVs surface, the formation and size of EVs and the 
size associated to PCA. Among these techniques, TGA proved to be a useful 
technique to study EVs-PCA origins and size. 
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In the second study, we aimed to optimise TGA by increasing sensitivity for 
TF detection, as TGA lack to study low EVs TF activity. We showed that 
inhibition of TFPI in NPP increased the sensitivity of EV-TF activity 
detection and decreased the variability of TGA.  
The third study used TEM, FCM and TGA to illustrate that leukemic cells 
can shed EVs with PCA in vitro. By this combination of techniques, we 
assessed that leukemic cells can shed PCA EVs and this EVs came from TF 
and PLs on EVs surface. This study strongly supports the implication of EVs 
in thrombotic disease in leukemic patient.  
The last study of this thesis showed that EVs PCA could be a promising 
biomarker to prevent thrombosis in AL patient. Only one score model is 
validated to predict thrombosis in cancer patient, the Khorana risk model. 
However, it is available only for solid tumors (Khorana and Connolly 2009). 
Some of the parameters included in this risk model are irrelevant in AL since 
neutrophil count, platelet count and hemoglobin concentration are affected by 
the disease and their treatments. These data show that we must find 
biomarkers not affected by the pancytopenia and highlight the used of new 
potent biomarkers such as P-selectin or EVs-TF (Connolly and Khorana 
2010). Activity tests are more relevant than antigen assays and quantification 
by FCM (data not shown) to identify patients who developed thrombosis and 
to exclude patient without thrombotic event. This could be due to the multiple 
alternative spliced TF and the availability of Ab against TF (Bogdanov, 
Balasubramanian et al. 2003). Electron microscopy is not relevant to study 
EVs as biomarker. This technique cannot quantify EVs-TF and is too long in 
comparison to activity tests. 
 
7.1 Clinical perspectives 
 
Thrombin generation assay is a sensitive technique to evaluate the 
procoagulant activity from plasmatic EVs. However this technique should be 
coupled with an ultracentrifugation and with the use of antibody against TFPI 
which increase the TAT and the cost. The development of similar test 
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practical in clinic laboratory should be done with less time and cost 
expenditure.  
A rapid and low cost EVs-TF activity test should be assessed on a large cohort 
of cancer patient. Cancer patients and their EVs-TF activity should be 
followed for a long time to study and correlate their outcomes (such as 
thrombosis (arterial or venous), thrombosis related death, thrombosis related 
to treatment and relapses) to EVs-PCA. Moreover, patients with thrombotic 
diseases not related to cancer (i.e DIC) could be included in the validation of 
EVs-PCA biomarker (Delabranche, Boisrame-Helms et al. 2013). 
In parallel, a prospective clinical study could be proposed to assess the 
efficacy of anticoagulant to prevent blood clots in the veins in participants 
who have hematologic cancer and a high levels EVs-TF activity. 
 
7.2 Biological perspectives 
 
Vascular endothelial activation probably contributes to the procoagulant 
phenotype in haematological malignancies. Indeed, some in vivo results 
suggest an endothelium activation in haematological malignancies. Increased 
levels of circulating P-selectin and VWF have been observed in patients’ 
blood compared to controls and would reflect this endothelial activation 
(Blann, Gurney et al. 2001). A procoagulant activity of endothelial cells after 
anthracyclines treatment has also been highlighted (Swystun, Shin et al. 2009) 
and an increased release of procoagulant endothelial EVs was observed after 
daunorubicin treatment. EVs generated by cancer cells could contribute to 
this endothelium activation by transfer of procoagulant protein, or by transfer 
of miRNA. This new insight into endothelial activation mechanism in cancer 
might be an interesting field of investigation (Bouvy, Gheldof et al. 2014). 
EVs are also known to be a pathway for cell communication and are able to 
impact remote target cells’ phenotype by carrying and transfer protein and 
nucleic acid (mRNA, miRNA) (Ratajczak, Wysoczynski et al. 2006). This 
impact of phenotype could be a way for drug multiresistance spreading 
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among tumor cells. This hypothesis is currently under investigation by our 
group in lymphoma and could be extended to other cancers. First result seems 
promising to confirm the transmission of multidrug resistance from resistant 
HL-60 to sensible HL-60 by EVs. 
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